KOL | Hiroshi FujishimaDepartment of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa 230-0063, Japan;, fujishima117@gmail.com | Department of Ophthalmology, Keio University ... |
Currículum de kol para Hiroshi Fujishima
| Year | |
|---|---|
| 2021 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa 230-0063, Japan;, Ophthalmology, Tsurumi University Dental Hospital, Yokohama, Kanagawa, Japan |
| 2020 | Department of Ophthalmology, Keio University School of Medicine, Tokyo 160-0016, Japan;, (E.S.);, (N.A.);, (Y.O.) Fujishima Eye Clinic, Niigata 949-6600, Japan |
| 2019 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Tsurumi-ku 230-8501, Kanagawa, Japan;, (N.K.);, (A.S.);, (H.F.) Tsurumi University School of Dental Medicine, Yokohama, Japan |
| 2016 | Department of Ophthalmology, Tsurumi University Dental Hospital, Kanagawa, Japan |
| 2015 | From the *Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa; and †Department of Ophthalmology, Tokyo Saiseikai Central Hospital; and ‡J&J Ocular Surface and Visual Optics Department, Keio University School of Medicine, Tokyo, Japan. |
| 2014 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Yokohama, Japan |
| 2012 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa |
| 2011 | Department of Ophthalmology, Tsurumi University Dental Hospital, Kanagawa, Japan. |
| 2010 | Department of Ophthalmology, International University of Health and Welfare, Mita Hospital, Tokyo, Japan. |
| 2009 | Department of Ophthalmology, Keio University, Tokyo, Japan. |
| 2008 | Department of Ophthalmology, International University of Welfare, Mita Hospital, Tokyo, Japan |
| 2007 | International University of Health and Welfare, Department of Ophthalmology, Mita Hospital, 1-4-3 Mita, Minato-ku, Tokyo 108-8329, Japan. |
| 2006 | From the *Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Japan; †Keio University School of Medicine, Tokyo, Japan; and ‡Hara Eye Clinic, Otawara, Tochigi Prefecture, Japan. Department of Ophthalmology, Keio University School of Medicine |
| 2005 | From the Department of Ophthalmology, Keio University, Tokyo, Japan; the Department of Ophthalmology, Tokyo Dental College, Sugano 5-11-13, Ichikawa, Chiba 272-8513, Japan |
| 2004 | From the Departments of *Ophthalmology and †Dermatology, Tokyo Dental College, Ichikawa, Chiba, Japan. Department of Ophthalmology, Keio University, Tokyo, Japan |
| 2003 | Department of Ophthalmology, Tokyo Dental College, Chiba, Japan |
| 2002 | Department of Ophthalmology, Tokyo Dental College, Sugano, Ichikawa, Japan. |
| 2001 | From the Departments of Ophthalmology (N.A-K., K.F., K.T., K.U., H.F.) and Dermatology (S.T.), Tokyo Dental College, Chiba, Japan. |
| 1998 | Department of Ophthalmology, Tokyo Dental College, Ichikawa, Chiba, Japan. |
| 1997 | Department of Ophthalmology, Tokyo Dental College, Chiba |
| 1996 | Department of Ophthalmology, Tokyo Dental College; Department of Ophthalmology, Keio University School of Medicine |
| 1995 | Chiba, Tokyo, and Akita, Japan Department of Ophthalmology Tokyo Dental College, Chiba |
| 1994 | Department of Ophthalmology, School of Medicine, Keio University, Tokyo, Japan. |
Hiroshi Fujishima: Estadísticas de influencia
Sacar un reporte
| Concept | World rank |
|---|---|
| vkc akc | #1 |
| commercial washing solution | #1 |
| tnfalpha tranilast dexamethasone | #1 |
| akc vkc | #1 |
| keratoconjunctivitis akc | #1 |
| dscg fml | #1 |
| diseases tear | #1 |
| allergens levocabastine | #1 |
| adeno eye | #1 |
| antagonists child conjunctivitis | #1 |
| scleritis tacrolimus | #1 |
| clinical signs akc | #1 |
| instillation bromfenac | #1 |
| instillation symptoms | #1 |
| selected fml | #1 |
| conjunctival fibroblasts | #1 |
| tacrolimus eye treatment | #1 |
| production ketotifen fumarate | #1 |
| akc allergic | #1 |
| conjunctivitis enrolled | #1 |
| exacerbation vkc | #1 |
| severity objective signs | #1 |
| subjective ocular symptoms | #1 |
| severe binocular conjunctivitis | #1 |
| capilia adeno eye | #1 |
| scores hyperemia | #1 |
| keratoconjunctivitis male | #1 |
| artificial tears positive | #1 |
| efficacy fml | #1 |
| bromfenac sodium treatment | #1 |
| 3 months signs | #1 |
| efficacy bromfenac sodium | #1 |
| ded anti | #1 |
| fml administered | #1 |
| conjunctivitis concomitantly | #1 |
| conjunctivitis scleritis episcleritis | #1 |
| fluorometholone 002 | #1 |
| levocabastine artificial tears | #1 |
| treatment vernal keratoconjunctivitis | #1 |
| akc treatment | #1 |
| epithelial pge2 | #1 |
| akc methods | #1 |
| levocabastine artificial | #1 |
| improvement combinedtreatment | #1 |
| therapy levocabastine | #1 |
| tears conjunctival fibroblasts | #1 |
| eye allerwatch | #1 |
| initiation tacrolimus treatment | #1 |
| allergic conjunctivitis | #1 |
| dscg bf | #1 |
| allerwatch tests | #1 |
| higher akc | #1 |
| allergic docosahexaenoic | #1 |
| stat6results | #1 |
| conjunctivitis seasonal | #1 |
| fml 002 | #1 |
| accuracy conjunctivitis | #1 |
| iop akc | #1 |
| keratoconjunctivitis vernal | #1 |
| tacrolimus eye drop | #1 |
| cytokinestimulation pharmacologic intervention | #1 |
| tears allergic patients | #1 |
| experience 01 | #1 |
| initiating tacrolimus | #1 |
| akc administration | #1 |
| eotaxin1 production | #1 |
| tranilast dexamethasone | #1 |
| radioimmunoassay il4 | #1 |
| systemic control pain | #1 |
| concomitant bf | #1 |
| vkc april | #1 |
| patients atopic keratoconjunctivitis | #1 |
| rate allerwatch | #1 |
| allergic postoperative | #1 |
| child conjunctivitis | #1 |
| dha western blotting | #1 |
| washing allergens | #1 |
| diagnostic accuracy conjunctivitis | #1 |
| production tranilast | #1 |
| keratoconjunctivitis background | #1 |
| cox2 conjunctival | #1 |
| eyewash solutions | #1 |
| 01 tacrolimus eye | #1 |
| satisfaction suspensions | #1 |
| eyebon eye | #1 |
| eyebon | #1 |
| ketotifen fumarate dexamethasone | #1 |
| eyewash solution bak | #1 |
| akc compared | #1 |
| patients allergic conjunctivitis | #1 |
| prostaglandin tears | #1 |
| objective findings conclusions | #1 |
| talymus | #1 |
| atopic keratoconjunctivitis | #1 |
| suspension treating | #1 |
| allergic conjunctivitis efficacy | #1 |
| hundredandseventy eyes | #1 |
| tacrolimus ophthalmic suspension | #1 |
| allergic tranilast | #1 |
| vkc cases | #1 |
| sodium bf | #1 |
| allerwatch positivity rate | #1 |
| signs palpebral | #1 |
| rapid ophthalmic | #1 |
| pge2 human conjunctival | #1 |
| ige allerwatch | #1 |
| tears allergic | #1 |
| bromfenac sodium bf | #1 |
| test capilia | #1 |
| 01 ophthalmic solution | #1 |
| fourgraded severity | #1 |
| suppressing pge2 production | #1 |
| cedrus conjunctivitis | #1 |
| patients capilia | #1 |
| tacrolimus eye drops | #1 |
| allergic conjunctivitis drop | #1 |
| tacrolimus eye | #1 |
| conjunctivitis treated | #1 |
| epithelium disorders | #1 |
| include conjunctival | #1 |
| eyewash | #1 |
| tranilast production | #1 |
| adult cedrus conjunctivitis | #1 |
| atopic keratoconjunctivitis akc | #1 |
| release inhibitor purpose | #1 |
| ocular allergic diseases | #1 |
| dha il4 | #1 |
| solution allergic | #1 |
| allerwatch diagnostic accuracy | #1 |
| immunocytochemical study rtpcr | #1 |
| hyperemia pain | #1 |
| drops elicited | #1 |
| pcr eotaxin1 | #1 |
| capilia adeno | #1 |
| drop levocabastine | #1 |
| cases severe conjunctivitis | #1 |
| conjunctivitis helper | #1 |
| eye surface years | #1 |
| akc patients | #1 |
| characterized conjunctival | #1 |
| compared fluorometholone | #1 |
| eyewash solutions bak | #1 |
| bf concomitantly | #1 |
| commercial eyewash solutions | #1 |
| bromobenzenes conjunctivitis | #1 |
| eye fml | #1 |
| commercial eyewash | #1 |
| severe akc | #1 |
| bak epithelium | #1 |
| akc vernal | #1 |
| fml patients | #1 |
| conclusions objective assessments | #1 |
| 10 objective signs | #1 |
| tranilast eotaxin1 | #1 |
| patients akc | #1 |
| nsaids systemic control | #1 |
| bromfenac sodium | #1 |
| primary human conjunctival | #1 |
| cd3 cd4bearing cells | #1 |
| bak epithelium disorders | #1 |
| allerwatch higher | #1 |
| keratocytes tnfα | #1 |
| akc tear | #1 |
| conjunctivitis aims | #1 |
| eyewash solution | #1 |
| tacrolimus tears | #1 |
| conjunctival fibroblasts production | #1 |
| conjunctivitis conjunctival | #1 |
| action child conjunctivitis | #1 |
| 12 patients akc | #1 |
| 0001 allerwatch | #1 |
| adverse events scores | #1 |
| vkc conclusions | #1 |
| incubated interleukin | #1 |
| solution ocular | #1 |
| adenovirus capilia | #1 |
| higher capilia | #1 |
| itching levocabastine | #1 |
| allergic enzyme | #1 |
| inhibition eotaxin1 | #1 |
| conjunctival cedar | #1 |
| tacrolimus ophthalmic solution | #1 |
| postoperative conjunctivitis | #1 |
| il4 tranilast | #1 |
| itchy sensation | #1 |
| dscg symptoms | #1 |
| eotaxin conjunctival fibroblasts | #1 |
| samples allergic conjunctivitis | #1 |
| conjunctivitis japanese | #1 |
| il4 causing | #1 |
| positivity rate allerwatch | #1 |
| akc | #1 |
| sodium ophthalmic solution | #1 |
| binocular conjunctivitis | #1 |
| allergenmediated conjunctivitis | #1 |
| severe conjunctivitis eyes | #1 |
| eye wash | #1 |
| fumarate dexamethasone | #1 |
| conjunctivitis including | #1 |
| il4 tear | #1 |
| dscg 005 | #1 |
| allergic corneal | #1 |
| sodium allergic | #1 |
| tacrolimus ophthalmic | #1 |
| bf fml | #1 |
| corneal epithelium disorders | #1 |
| rsv conjunctival | #1 |
| patients severe conjunctivitis | #1 |
| selective chemotactic effects | #1 |
| fml dscg | #1 |
| eye itching | #1 |
| production conjunctival fibroblasts | #1 |
| tacrolimus lessen | #2 |
| based papillae | #2 |
| blepharitis ceramides | #2 |
| scores papillary | #2 |
| regrowth 7 eyes | #2 |
| formation akc | #2 |
| improvement vital staining | #2 |
| epitheliopathy patients | #2 |
| corneal lesions | #2 |
| japan topical | #2 |
| lesions allergic | #2 |
| allergic conjunctivitis ige | #2 |
| selected bf | #2 |
| adjuvant betamethasone | #2 |
| 001 brush | #2 |
| topical antiallergic agents | #2 |
| conjunctivitis proliferative | #2 |
| conjunctival injection reduction | #2 |
| period rhodanine | #2 |
| diabetic patients ono2235 | #2 |
| treatment tear | #2 |
| decrease corneal temperature | #2 |
| limbal swelling | #2 |
| oral ari | #2 |
| ari ocular | #2 |
| treatment atopic blepharitis | #2 |
| conjunctivitis epitheliopathy | #2 |
| corneal findings | #2 |
| cutometer sem575 | #2 |
| talymus akc | #2 |
| epitheliopathy shield | #2 |
| methods thirtysix patients | #2 |
| conjunctival findings severity | #2 |
| normal blinking patients | #2 |
| papilla accompanied | #2 |
| mmc 7 eyes | #2 |
| correlation neutrophils | #2 |
| cedrus conjunctiva | #2 |
| signs decreased | #2 |
| excision cobblestonelike papillae | #2 |
| total signs symptoms | #2 |
| score adjustments | #2 |
| allergic conjunctivitis levocabastine | #2 |
| conjunctivitis purpose | #2 |
| tacrolimus topical | #2 |
| neutrophils brush | #2 |
| topical tacrolimus combination | #2 |
| complain foreign | #2 |
| solutions japan | #2 |
| severity corneal complications | #2 |
| vkc atopic keratoconjunctivitis | #2 |
| patients shield ulcers | #2 |
| allergic diagnosis | #2 |
| cac test | #2 |
| conjunctiva conjunctivitis allergic | #2 |
| lacrimation objective | #2 |
| premedication combined | #2 |
| sem575 clinical | #2 |
| bovine placebo | #2 |
| environmental studies prevalence | #2 |
| bromfenac ophthalmic solution | #2 |
| papillary excision | #2 |
| defined conjunctival | #2 |
| tacrolimus 12 weeks | #2 |
| ulcer complain | #2 |
| production specular | #2 |
| nonwash | #2 |
| brush cytology samples | #2 |
| 1 month tacrolimus | #2 |
| ophthalmic nsaid | #2 |
| ensured proving | #2 |
| edema height | #2 |
| epinastine superiority | #2 |
| papillae preventing | #2 |
| sodium ophthalmic | #2 |
| papillae limbus | #2 |
| drop steroid | #2 |
| 18 akc | #2 |
| month eyewash | #2 |
| conjunctivitis representative | #2 |
| steroid metaregression | #2 |
| cobblestonelike papillae | #2 |
| drops conjunctival | #2 |
| ceramide gel application | #2 |
| oral ari administration | #2 |
| conjunctival corneal cells | #2 |
| asthma heart diseases | #2 |
| brush cytology patients | #2 |
| eyelid atopic dermatitis | #2 |
| tear film layer | #2 |
| pollutants prevalence | #2 |
| air pollutants prevalence | #2 |
| mmc aided | #2 |
| diathesis subjective | #2 |
| regrowth papillae | #2 |
| tears thiazolidines | #2 |
| 062 tear | #2 |
| tacrolimus detection | #2 |
| sem575 | #2 |
| giant papillae formation | #2 |
| iop topical steroids | #2 |
| seasonal allergic conjunctivitis | #2 |
| papillae akc | #2 |
| dryness scores | #2 |
| bromfenac effective | #2 |
| adjustments epitheliopathy score | #2 |
| corneal epitheliopathy score | #2 |
| tacrolimus tonometry | #2 |
| bovine entericcoated lactoferrin | #2 |
| olopatadine ocular | #2 |
| epitheliopathy steroids | #2 |
| akc young adult | #2 |
| japan topical tacrolimus | #2 |
| eyelid skin elasticity | #2 |
| severity eyelid | #2 |
| solution epinastine | #2 |
| ecp severity markers | #2 |
| formation palpebral | #2 |
| inflammatory child child | #2 |
| pge2 tears | #2 |
| adjustments epitheliopathy | #2 |
| aided papillary | #2 |
| allergy accompanied | #2 |
| sodium bromfenac | #2 |
| elasticity severity | #2 |
| tacrolimus detection limit | #2 |
| plaques 791 | #2 |
| edema corneal damage | #2 |
| epitheliopathy refractory | #2 |
| hyperemia lacrimation | #2 |
| treatment shield ulcer | #2 |
| betamethasone glaucoma | #2 |
| objective signs baseline | #2 |
| proliferative called | #2 |
| papillae mucous discharge | #2 |
| tacrolimus iop | #2 |
| sac healthy | #2 |
| corneal temperature patients | #2 |
| patients severe akc | #2 |
| mucous discharge severity | #2 |
| corneal epitheliopathy | #2 |
| eyes betamethasone | #2 |
| refractory allergic | #2 |
| lid skin | #2 |
| conjunctivitis retrospective | #2 |
| fluorescein conjunctival injection | #2 |
| administered elf bovine | #2 |
| akc levels | #2 |
| conventional antiallergic drugs | #2 |
| tacrolimus shield | #2 |
| epinastine ophthalmic solution | #2 |
| study designopen cohort | #2 |
| patients shield | #2 |
| scores tacrolimus | #2 |
| folliculosis papillae | #2 |
| lactoferrin 01 | #2 |
| superiority epinastine | #2 |
| atopic diagnostic techniques | #2 |
| reported eotaxin | #2 |
| tacrolimus 1 month | #2 |
| adjuvant fluorometholone | #2 |
| akc sac patients | #2 |
| disease antiallergic | #2 |
| baseline papillae | #2 |
| detected akc | #2 |
| correlation eosinophils | #2 |
| giant papillary formation | #2 |
| akc patients correlation | #2 |
| unpaired ttest talymus | #2 |
| test papillae | #2 |
| akc 10 eyes | #2 |
| including akc | #2 |
| effects tacrolimus | #2 |
| largescale study protocol | #2 |
| patients corneal ulcers | #2 |
| conjunctiva papillary | #2 |
| total clinical signs | #2 |
| patients tacrolimus eye | #2 |
| metaregression analysis glaucoma | #2 |
| simple resection regrowth | #2 |
| allergic endophthalmitis | #2 |
| suspension talymus | #2 |
| corneal recurrences | #2 |
| placebo noninferiority | #2 |
| akc aureus | #2 |
| akc adult | #2 |
| conjunctival injection edema | #2 |
| bromfenac sodium bromfenac | #2 |
| treatment ecp concentrations | #2 |
| conjunctivitis 10 | #2 |
| skin elasticity patients | #2 |
| olopatadine visit | #2 |
| allergic conjunctivitis akc | #2 |
| resolution thermography | #2 |
| efficacy severe akc | #2 |
| accompanied subjective | #2 |
| recurrence corneal complications | #2 |
| elevation tacrolimus | #2 |
| endpoint itching scale | #2 |
| akc adolescent | #2 |
| representative subjective | #2 |
| neutrophils corneal damage | #2 |
| cornea grading | #2 |
| extents corneal | #2 |
| corneal complications height | #2 |
| mucin analyzed | #2 |
| excision cobblestone | #2 |
| treated bromfenac | #2 |
| oral ari ono2235 | #2 |
| eyes 824 | #2 |
| muc16 immunohistochemistry | #2 |
| 2helper cell | #2 |
| drops hyperemia | #2 |
| corneal lesions regrowth | #2 |
| corneal ulcers patients | #2 |
| effects topical tacrolimus | #2 |
| nonpreserved eyewash solution | #2 |
| ecp levels akc | #2 |
| treatment total signs | #2 |
| swelling folliculosis | #2 |
| akc allergic diagnosis | #2 |
| dermatitis remission | #2 |
| recurrence corneal lesions | #2 |
| olopatadine cedar | #2 |
| akc 1 | #2 |
| steroids epitheliopathy | #2 |
| akc 6 | #2 |
| factor vkc | #2 |
| shield ulcers patients | #2 |
| ketotifen dexamethasone | #2 |
| vkc 5 | #2 |
| tarsal brush | #2 |
| lower conjunctival sacs | #2 |
| improvement corneal fluorescein | #2 |
| ocular surface mucin | #2 |
| deqs tear | #2 |
| papillae severe | #2 |
| atopic blepharitis | #2 |
| rhodanine rose | #2 |
| sem575 quantitatively | #2 |
| signs blood concentration | #2 |
| corneal damage patients | #2 |
| oral aldose | #2 |
| aureussecreted enterotoxins | #2 |
| corneal damage height | #2 |
| suspension lactoferrin | #2 |
| epinastine 15 minutes | #2 |
| akc treated | #2 |
| prevalence akc | #2 |
| eyelid elasticity | #2 |
| benzophenones bromobenzenes | #2 |
| csa akc | #2 |
| severe allergic conjunctivitis | #2 |
| keratoconjunctivitis corneal | #2 |
| severity corneal lesions | #2 |
| administration specular | #2 |
| elasticity eyelid | #2 |
| conjunctiva bulbar | #2 |
| post cataract surgery | #2 |
| epitheliopathy score | #2 |
| conjunctivitis adolescent | #2 |
| conjunctiva atopic | #2 |
| noninferiority olopatadine | #2 |
| diagnosis ensured | #2 |
| cytodiagnosis dermatitis | #2 |
| vkc japan | #2 |
| serum allergic parameters | #2 |
| administered elf | #2 |
| eyelid atopic | #2 |
| height papillae | #2 |
| conclusions bromfenac | #2 |
| conjunctivitis condition | #2 |
| tear ige correlation | #2 |
| eosinophils corneal damage | #2 |
| correlation fluorescein | #2 |
| 95 adjuvant betamethasone | #2 |
| lessen steroid | #2 |
| eyewash 005 | #2 |
| akc 10 | #2 |
| epitheliopathy corneal | #2 |
| corneal epithelial signs | #2 |
| score topical | #2 |
| tacrolimus published data | #2 |
| control subjects eyes | #2 |
| japan akc | #2 |
| keratoconjunctivitis age | #2 |
| papillary formation | #2 |
| concomitantly abovementioned | #2 |
| female humans akc | #2 |
| drop concomitantly | #2 |
| evaluate superiority | #2 |
| drops refractory | #2 |
| adjuvant fluorometholone 95 | #2 |
| immunoregulatory effects study | #2 |
| tears akc | #2 |
| simple papillary resection | #2 |
| severity corneal damage | #2 |
| child conjunctiva | #3 |
| pilocarpine visante | #3 |
| elisa histamine | #3 |
| periostin akc | #3 |
| par2 cultured | #3 |
| technique 2 eyes | #3 |
| dfna eye dfna | #3 |
| ophthalmic solution placebo | #3 |
| dramatic healing | #3 |
| corneal complications1 | #3 |
| nonpreserved artificial tears | #3 |
| treatment atopic keratoconjunctivitis | #3 |
| papillae morphometric | #3 |
| relevant factor exacerbation | #3 |
| sdedry eye | #3 |
| diclofenac eye drops | #3 |
| nuclei vkc | #3 |
| evaluate tear | #3 |
| par2 benzamidines blotting | #3 |
| vivo corneal akc | #3 |
| cooling cataract | #3 |
| vkc differences | #3 |
| lnfs nbs | #3 |
| interleukin4 tacrolimus | #3 |
| hydrochloride 01 | #3 |
| 12 akc patients | #3 |
| scale tmh | #3 |
| akc persistent | #3 |
| treatment oral pilocarpine | #3 |
| prospectively diclofenac | #3 |
| vkc papillae | #3 |
| dscg administration | #3 |
| drop selected | #3 |
| higher muc1 eyes | #3 |
| phenomena tacrolimus | #3 |
| conjunctival fibroblasts rtpcr | #3 |
| allergic cornea | #3 |
| topical cyclosporine 01 | #3 |
| healing dramatic healing | #3 |
| outpatient attendance july | #3 |
| vkc relevant factor | #3 |
| permeability postoperatively | #3 |
| healing allergic | #3 |
| uncontrollable glaucoma | #3 |
| ophthalmic solution nsaid | #3 |
| akc eyes | #3 |
| akc dyes humans | #3 |
| signs remission | #3 |
| allergic postsurgical | #3 |
| cornea atopic | #3 |
| conjunctiva allergic | #3 |
| treatment vernal | #3 |
| tear il13 | #3 |
| eosinophils corneal | #3 |
| mmc authors | #3 |
| techniques tears | #3 |
| hyperemia allergic | #3 |
| tear periostin comorbidities | #3 |
| increased comfort | #3 |
| papillae upper | #3 |
| pretreatment docosahexaenoic acid | #3 |
| membrane uncontrollable | #3 |
| akc higher | #3 |
| lacrimal punctal occlusion | #3 |
| 5ac mrna | #3 |
| ulcers eyes | #3 |
| akc periostin | #3 |
| eyes allergic | #3 |
| vkc long | #3 |
| akc comorbidities | #3 |
| samples correlate | #3 |
| ulcers plaques | #3 |
| fluorescein scale | #3 |
| flare metry | #3 |
| ssdry | #3 |
| ulcer persistent | #3 |
| injections keratoconjunctivitis | #3 |
| prophylaxis conjunctival | #3 |
| reaction conjunctiva | #3 |
| severe allergic patients | #3 |
| improvement squamous metaplasia | #3 |
| cell flare count | #3 |
| periostin topical | #3 |
| vkc eyes | #3 |
| rose bengal akc | #3 |
| akc alterations | #3 |
| vkc exacerbation | #3 |
| akc confocal | #3 |
| antiallergic eye drop | #3 |
| muc1 brush cytology | #3 |
| outpatient visits july | #3 |
| association outpatient attendance | #3 |
| 005 mmc | #3 |
| conjunctivitis pm25 | #3 |
| eye washing | #3 |
| local tear deficiency | #3 |
| akc higher muc1 | #3 |
| akc confocal microscopy | #3 |
| temperature evaluate | #3 |
| dfna eye | #3 |
| nbs normal eyes | #3 |
| epithelium adverse | #3 |
| patching case | #3 |
| 5 eyes akc | #3 |
| efficacy bromfenac | #3 |
| pm25 allergic | #3 |
| ecp severity | #3 |
| measurements schirmer | #3 |
| induced inflammation lenses | #3 |
| commercial washing | #3 |
| ebv ade | #3 |
| thermography evaluate | #3 |
| treatment strip meniscometry | #3 |
| fibronectin vkc | #3 |
| superficial cells conjunctiva | #3 |
| study cutometer | #3 |
| underwent staining | #3 |
| cholinergic treatment response | #3 |
| insufficient tear | #3 |
| tissue remodeling exacerbation | #3 |
| dfna diclofenac epithelium | #3 |
| 005 ophthalmic solution | #3 |
| akc tear periostin | #3 |
| weekly average values | #3 |
| insensible administration insensible | #3 |
| decline corneal | #3 |
| cells brush cytology | #3 |
| cultured tryptase | #3 |
| pollen august | #3 |
| conjunctival corneal | #3 |
| diseases acds | #3 |
| existence par2 | #3 |
| conjunctivitis lymphocytes | #3 |
| vkc levels | #3 |
| ulcer akc | #3 |
| patients pilocarpine tablets | #3 |
| eyes vkc | #3 |
| formation vkc | #3 |
| pollen postoperative | #3 |
| operation eye | #3 |
| corneal epithelial structure | #3 |
| aged elisa | #3 |
| allergic patients conjunctivitis | #3 |
| histamine conjunctival cells | #3 |
| insufficient tear supply | #3 |
| 005 collagens | #3 |
| tryptase increases | #3 |
| sligkv examined | #3 |
| tears treatment | #3 |
| immunosuppressive eye | #3 |
| histamine cedar | #3 |
| allergic conjunctivitis aged | #3 |
| conjunctivitis allergic | #3 |
| eyes control subjects | #3 |
| formation vernal | #3 |
| conjunctivitis benzamidines | #3 |
| tear periostin biomarker | #3 |
| tmh measurement | #3 |
| akc serum periostin | #3 |
| interleukin4 histamine | #3 |
| infrared radiation thermography | #3 |
| macroerosions | #3 |
| outpatient visits august | #3 |
| rtpcr par2 | #3 |
| laser cellflaremetry | #3 |
| glaucoma amniotic | #3 |
| 13 eyes 69 | #3 |
| tears adolescent | #3 |
| ocular surface diabetes | #3 |
| aged biological dressings | #3 |
| il1beta th2 | #3 |
| fibronectin normal controls | #3 |
| 01 ophthalmic | #3 |
| conjunctival disease | #3 |
| metry dfna | #3 |
| 3 sjögrens syndrome | #3 |
| strip meniscometry testing | #3 |
| cases vkc | #3 |
| fluorescein glycyrrhizic | #3 |
| vkc fibronectin | #3 |
| histamine cedar pollen | #3 |
| periostin comorbidities | #3 |
| severe allergy patients | #3 |
| proving type | #3 |
| portable recordable | #3 |
| cytology impression | #3 |
| aureus akc patients | #3 |
| laser flarecellmetry | #3 |
| giant papilla | #3 |
| lamp device | #3 |
| tryptase conjunctiva | #3 |
| cell metry | #3 |
| mmc excision | #3 |
| benzamidine par2 | #3 |
| underwent periodic | #3 |
| technique uncontrollable | #3 |
| 5ac brush | #3 |
| histamine specimens | #3 |
| papillary regrowth | #3 |
| cases vernal | #3 |
| lower muc5ac | #3 |
| protein conjunctival fibroblasts | #3 |
| fibers lnfs | #3 |
| mmcaided papillary resection | #3 |
| surgery dfna | #3 |
| allerwatch | #3 |
| diabetic corneal disease | #3 |
| sde controls | #3 |
| nbs subbasal | #3 |
| eyes akc | #3 |
| differences dfna | #3 |
| papillary resection | #3 |
| allergic corneal diseases | #3 |
| 12 akc | #3 |
| 1 month initiation | #3 |
| drops treat | #3 |
| 22 eyes 100 | #3 |
| allergic corneal ulcer | #3 |
| conjunctiva conjunctivitis | #3 |
| akc rose bengal | #3 |
| epinastine placebo | #3 |
| solutions prospective | #3 |
| techniques conjunctivitis | #3 |
| existence par2 mrna | #3 |
| vkc sac | #3 |
| il1beta th2 cytokines | #3 |
| central corneal temperature | #3 |
| patients tmh measurements | #3 |
| oct graticule | #3 |
| traumatic swelling | #3 |
| histamine superficial cells | #3 |
| autumnal pollen | #3 |
| vkc cell | #3 |
| treatment skin elasticity | #3 |
| sensitivity tear | #3 |
| 21 akc patients | #3 |
| conjunctivitis negative | #3 |
| keratoconjunctivitis vkc | #3 |
| titers ade | #3 |
| corneal ulceration role | #3 |
| oct tmh | #3 |
| inflammation mmc | #3 |
| 111 177 | #3 |
| diclofenac epithelium | #3 |
| keratoconjunctivitis leupeptins | #3 |
| 21 akc | #3 |
| scored global | #3 |
| dry eye eye | #3 |
| ari corneal | #3 |
| patching patient | #3 |
| corneal akc | #3 |
| antieaigg | #3 |
| tear periostin patients | #3 |
| normal controls collagens | #3 |
| vkc 5 eyes | #3 |
| superior limbic portion | #3 |
| icecold eye mask | #3 |
| eye cooling | #3 |
| july pm25 | #3 |
| pm25 outpatient attendance | #3 |
| postsurgical conjunctivitis | #3 |
| erosions refractory | #3 |
| dibenzoxepins female | #3 |
| healed amniotic | #3 |
| tear periostin | #3 |
| production conjunctival | #3 |
| 01 bromfenac | #3 |
| antibody titers ade | #3 |
| conjunctival fibroblasts tryptase | #3 |
| dfna control | #3 |
| adedry eye | #3 |
| akc atopic dermatitis | #3 |
| akc biomarkers | #3 |
| alterations tear | #3 |
| uncontrollable glaucoma trabeculectomy | #3 |
| superior keratoconjunctiva | #3 |
| treatment vmr | #4 |
| akc immunologic receptors | #4 |
| level conjunctiva | #4 |
| corneal sensitivity measurements | #4 |
| epithelial disease patients | #4 |
| conjunctiva differences | #4 |
| simple resection | #4 |
| staining muc | #4 |
| trantas | #4 |
| microscope evaluating | #4 |
| ophthalmologists eye drops | #4 |
| allergic cytological | #4 |
| conventional portable | #4 |
| goblet cell muc5ac | #4 |
| conjunctival papillary | #4 |
| conjunctiva density | #4 |
| muc5ac brush cytology | #4 |
| il4 tears | #4 |
| eyes insignificant | #4 |
| ulcers atopic | #4 |
| inflammation akc | #4 |
| vkc 4 | #4 |
| formation conjunctivitis | #4 |
| allergic conjunctivitis rsv | #4 |
| akc sac | #4 |
| vkc normal controls | #4 |
| papillae giant | #4 |
| fibroblasts primary sources | #4 |
| controls brush cytology | #4 |
| adolescent betamethasone | #4 |
| conjunctivitis methods | #4 |
| conjunctivitis ige | #4 |
| ocular surface epithelial | #4 |
| epithelial pge2 production | #4 |
| individuals pgd2 | #4 |
| akc chemotaxis | #4 |
| epithelial cells rsv | #4 |
| akc healthy | #4 |
| allergic conjunctival diseases | #4 |
| defensins conjunctivitis | #4 |
| staining muc16 | #4 |
| tnfalpha30ng | #4 |
| 4 chemokines stimulation | #4 |
| exponential equation inclination | #4 |
| lesions regrowth | #4 |
| placebo ophthalmic | #4 |
| akc rtpcr | #4 |
| noninfectious necrotizing | #4 |
| mucins 1 | #4 |
| oedema papillary | #4 |
| tomography tear | #4 |
| severe ocular allergies | #4 |
| giemsas staining | #4 |
| allergic rhinoconjunctivitis allergic | #4 |
| rsv conjunctiva | #4 |
| atopic keratoconjunctivitis purpose | #4 |
| akc pgd2dependent migration | #4 |
| thinoptx | #4 |
| correlation outpatient | #4 |
| levocabastine ophthalmic | #4 |
| cytology goblet | #4 |
| allergic patients elisa | #4 |
| eosinophils receptor crth2 | #4 |
| vmr 3 months | #4 |
| thinoptx acrysof | #4 |
| keratoconjunctivitis purpose | #4 |
| studied corneal | #4 |
| pcr epithelial | #4 |
| muc16 goblet | #4 |
| erosion shield | #4 |
| defensins greater | #4 |
| vkc male receptors | #4 |
| surface muc5ac | #4 |
| p0001 impression | #4 |
| tears 10 patients | #4 |
| sensation tears | #4 |
| par2 mrna protein | #4 |
| excision papillary | #4 |
| conjunctiva allergic conjunctivitis | #4 |
| topical oral steroids | #4 |
| rose bengal scores | #4 |
| scores conjunctival | #4 |
| acds ophthalmologists | #4 |
| eotaxin1 rantes | #4 |
| 061 028 degree | #4 |
| rsv conjunctiva conjunctivitis | #4 |
| akc healthy individuals | #4 |
| corneal temperature blink | #4 |
| conjunctivitis vkc | #4 |
| muc1 2 | #4 |
| 34 15 seconds | #4 |
| folliculosis | #4 |
| chemokine genes fibroblasts | #4 |
| keratoconjunctivitis lacrimal | #4 |
| cornea grading scale | #4 |
| interferometry 2 | #4 |
| atopic ocular allergies | #4 |
| allergic conjunctivitis prostaglandin | #4 |
| primary sources chemokines | #4 |
| ophthalmologists evaluated | #4 |
| limbal grafts | #4 |
| eye sjögrens syndrome | #4 |
| rejection limbal | #4 |
| corneal temperature eye | #4 |
| performed tears | #4 |
| muc5ac mrna expression | #4 |
| implantation rollable | #4 |
| male ophthalmic | #4 |
| patients topical cyclosporine | #4 |
| staining ocular | #4 |
| genes conjunctival | #4 |
| eyes ulcers | #4 |
| rsv conjunctival epithelium | #4 |
| 0001 brush | #4 |
| conjunctival proliferative | #4 |
| fva treatment | #4 |
| pgd2dependent migration eosinophils | #4 |
| samples immunocytochemical | #4 |
| sensitization asian dust | #4 |
| allergic conjunctival | #4 |
| subjects muc5ac | #4 |
| interferometry lipids | #4 |
| grade dry eye | #4 |
| untreated asian dust | #4 |
| tears patients | #4 |
| metaplasia reduction | #4 |
| tear function test | #4 |
| bromfenac eye drops | #4 |
| patients epithelial disease | #4 |
| interleukin2 tears | #4 |
| patients severe vkc | #4 |
| tears pathogenesis | #4 |
| steroids fluorometholone | #4 |
| tryptase dose | #4 |
| atopic dermatitis remission | #4 |
| aged rose | #4 |
| persistent 6 | #4 |
| stimulation chemokine expression | #4 |
| pgd2dependent migration | #4 |
| clinical conjunctival | #4 |
| alterations atopic | #4 |
| 33 chemokines | #4 |
| tacrolimus conclusions | #4 |
| sac grade | #4 |
| ulcers mucin | #4 |
| diseases portable | #4 |
| 020 013 | #4 |
| sio2 20 | #4 |
| eyes thinoptx | #4 |
| treatment vmr values | #4 |
| chemotaxis conjunctiva | #4 |
| p0001 brush | #4 |
| mucins tears mucin | #4 |
| greater 3 grade | #4 |
| tear temperature | #4 |
| 10 seconds temperature | #4 |
| pgd2 normal volunteers | #4 |
| membrane patching | #4 |
| diameter allergen | #4 |
| ded 1 | #4 |
| ulcers control subjects | #4 |
| eyes epithelial disease | #4 |
| allergic fibroblasts | #4 |
| greater concentrations tears | #4 |
| thinoptx lens | #4 |
| interferometry controls | #4 |
| cells lnfs | #4 |
| cell muc5ac | #4 |
| recordable slit | #4 |
| eye operation | #4 |
| rsv allergic reaction | #4 |
| atopic vernal | #4 |
| assay pgd2 | #4 |
| ocular allergic disease | #4 |
| vkc conjunctiva conjunctivitis | #4 |
| corneal ulcers eyes | #4 |
| eye wash solution | #4 |
| weeks vital | #4 |
| muc16 muc5ac alterations | #4 |
| tablets tears | #4 |
| sterilized asian dust | #4 |
| patient eyes fluorescein | #4 |
| fungi epidemiologic studies | #4 |
| muc5ac brush | #4 |
| underwent corneal | #4 |
| epithelial muc | #4 |
| mucin mucins tears | #4 |
| bengal sensation | #4 |
| papillae normal | #4 |
| acuity akc | #4 |
| metaregression analysis effects | #4 |
| bromfenac ophthalmic | #4 |
| hypersensitivity mucin | #4 |
| completely severe | #4 |
| crth2 akc | #4 |
| samples histocytological | #4 |
| steroids iop | #4 |
| histamine h1 antagonist | #4 |
| corneal safety | #4 |
| crth2 peripheral | #4 |
| moisture checker | #4 |
| dscg day | #4 |
| specimens underwent | #4 |
| allergic conjunctival disease | #4 |
| sac control eyes | #4 |
| insignificant epithelial | #4 |
| immunologic receptors akc | #4 |
| asian dust extract | #4 |
| ari ono2235 | #4 |
| eyes akc patients | #4 |
| 3004 respondents | #4 |
| thermography anterior | #4 |
| akcaffected patients | #4 |
| levocabastine h1 | #4 |
| pathogenesis noninfectious | #4 |
| lower tear function | #4 |
| corneal sensitivity measurement | #4 |
| 18 akc patients | #4 |
| portable slit | #4 |
| insignificant epithelial disease | #4 |
| temperature corneal | #4 |
| infected conjunctival | #4 |
| blinding purpose | #4 |
| hydrochloride ophthalmic | #4 |
| deqs scores | #4 |
| ige conjunctival | #4 |
| interferometry grade | #4 |
| vkc messenger reverse | #4 |
| 2010 allergic | #4 |
| epithelial muc16 | #4 |
| months papillary | #4 |
| compared vkc | #4 |
| cytometry mild cases | #4 |
| include ocular | #4 |
| sterilized asian | #4 |
| drop artificial tears | #4 |
| epithelial disease eyes | #4 |
| thermometer 20 | #4 |
| cases sufficient examination | #4 |
| special brush | #4 |
| corneal ulcers muc5ac | #4 |
| cytometry mild | #4 |
| patient atopic keratoconjunctivitis | #4 |
| allergies blinding | #4 |
| topical 01 tacrolimus | #4 |
| cultured conjunctival | #4 |
| samples allergic | #4 |
| akc crth2 | #4 |
| conjunctivitis levels | #4 |
| lower tear clearance | #4 |
| healthy individuals rtpcr | #4 |
| allergic epidemiologic studies | #4 |
| eosinophil toxic activity | #4 |
| disease akc | #4 |
| epinastine hydrochloride | #4 |
| eyes video | #4 |
| july pollen | #4 |
| eyes sac | #4 |
| muc5ac alterations | #4 |
| highrisk glaucoma patients | #4 |
| controls interferometry grade | #4 |
| tear function patients | #4 |
| acds conventional | #4 |
| controls interferometry | #4 |
| atopic ocular | #4 |
| proteinchip array elisa | #4 |
| implantation thinoptx | #4 |
| severe vkc patients | #4 |
| wilcoxon signed test | #4 |
| solutions piperidines | #4 |
| photophobia diagnosis | #4 |
| surface conjunctival | #4 |
| dust wheal | #4 |
| akc crth2 expression | #4 |
| thinoptx intraocular | #4 |
| 2 4 alterations | #4 |
| eyes corneal ulcers | #4 |
| ocular surface disorder | #5 |
| 7 conjunctival | #5 |
| eye warmer | #5 |
| study epinastine | #5 |
| accompanying allergic | #5 |
| bromobenzenes cornea | #5 |
| ulcer dermatitis | #5 |
| 01 mcfg | #5 |
| cytokinestimulation | #5 |
| hel ihc | #5 |
| disposable eyelid | #5 |
| months amniotic | #5 |
| solutions pollen | #5 |
| conjunctiva mmc | #5 |
| treatment shield | #5 |
| tears received | #5 |
| scores expressibility | #5 |
| alpha allergic | #5 |
| conjunctival allergen | #5 |
| age 9 ± | #5 |
| 20 sio2 | #5 |
| vkc iop | #5 |
| alterations ocular | #5 |
| crth2 prostaglandin receptors | #5 |
| intraoperative mitomycin excision | #5 |
| diclofenac eye | #5 |
| 310±165 years | #5 |
| human conjunctival fibroblasts | #5 |
| warmer improved | #5 |
| akc disease | #5 |
| fibroblasts eosinophil adherence | #5 |
| treatment dryeye symptoms | #5 |
| thinoptx iol | #5 |
| 005 schirmer1 | #5 |
| controls ebv | #5 |
| hel cytokines | #5 |
| impression brush | #5 |
| diseases required | #5 |
| trantas dots | #5 |
| ocular anesthesia | #5 |
| topical cyclosporine therapy | #5 |
| conjunctival inflammatory status | #5 |
| eosinophils activated fibroblasts | #5 |
| case corneal ulcer | #5 |
| severe conjunctivitis | #5 |
| cornea cytodiagnosis | #5 |
| signs akc | #5 |
| eye circulating | #5 |
| 20 akc patients | #5 |
| upper palpebral | #5 |
| 3 cases followup | #5 |
| cells vkc | #5 |
| layer mgd | #5 |
| month tear | #5 |
| allergic conjunctivitis patients | #5 |
| local tear | #5 |
| conjunctivitis pollen | #5 |
| akc patients study | #5 |
| schirmer1 test groups | #5 |
| visits august | #5 |
| samples akc | #5 |
| conventional steroid treatment | #5 |
| controls inflammatory cells | #5 |
| conjunctival lipid | #5 |
| eosinophil adherence fibroblasts | #5 |
| visits july | #5 |
| stainings tear | #5 |
| injection conjunctival | #5 |
| antifungal mcfg | #5 |
| conjunctivitis prostaglandin | #5 |
| temperature blink | #5 |
| damaged eosinophil | #5 |
| dryeye symptoms treatment | #5 |
| oct lower | #5 |
| corneal fibroblasts icam1 | #5 |
| 15 minutes dose | #5 |
| cases tests | #5 |
| stained conjunctival | #5 |
| ophthalmic test | #5 |
| 5 females akc | #5 |
| postsurgical inflammation | #5 |
| status confocal | #5 |
| eosinophil adhesion fibroblasts | #5 |
| keratoconjunctivitis objective | #5 |
| accompanied varying | #5 |
| equipment dry | #5 |
| 329±57 years | #5 |
| corneal involvement | #5 |
| females akc | #5 |
| inflammatory cells hel | #5 |
| conjunctiva dermatitis | #5 |
| thiazolidines administration | #5 |
| asthenopia dry | #5 |
| array chemotaxis | #5 |
| worse akc | #5 |
| prostaglandin chemotaxis | #5 |
| pretreatment dha | #5 |
| hne ihc | #5 |
| vkc atopic | #5 |
| supernatants conjunctival | #5 |
| measurements strip | #5 |
| 17 mgd patients | #5 |
| akc normal subjects | #5 |
| inflammation mitomycin | #5 |
| mcfg eye | #5 |
| staining muc5ac | #5 |
| lesion corneal | #5 |
| anterior fluorometry | #5 |
| ocular allergic | #5 |
| bengal suture | #5 |
| allergic drug therapy | #5 |
| punctal occlusion oct | #5 |
| vcam1 fibroblasts | #5 |
| dryeye symptoms | #5 |
| il4 histamine | #5 |
| adolescent conjunctivitis | #5 |
| treatment epinastine | #5 |
| disposable eyelidwarming device | #5 |
| akc acinar | #5 |
| wilcoxonmatched pair test | #5 |
| lipid oxidation hel | #5 |
| staining administration | #5 |
| severe stevensjohnson syndrome | #5 |
| stimulated conjunctival | #5 |
| conjunctival confocal microscopy | #5 |
| treatment tacrolimus ointment | #5 |
| 0001 strip | #5 |
| anterior scleritis patients | #5 |
| tnfα costimulation | #5 |
| situ nickend regulation | #5 |
| allergic keratopathy | #5 |
| akc laser | #5 |
| fibroblasts fibroblast damage | #5 |
| scans akc | #5 |
| ihc conjunctival inflammation | #5 |
| labeling surface akc | #5 |
| allergic female | #5 |
| eye warmer treatment | #5 |
| disease conjunctivitis | #5 |
| eosinophils immunologic receptors | #5 |
| ophthalmic suspension | #5 |
| meniscus punctal | #5 |
| adhered corneal | #5 |
| akc ecp | #5 |
| simple papillary | #5 |
| regulation allergic cornea | #5 |
| pm25 outpatient | #5 |
| lower atopic | #5 |
| mitomycin excision | #5 |
| histamine superficial | #5 |
| akc hel | #5 |
| allergic cyclosporine | #5 |
| keratoconjunctivitis giant | #5 |
| ulcers controls | #5 |
| younger age effects | #5 |
| solution olopatadine | #5 |
| cornea explain | #5 |
| damage impression | #5 |
| pgd2 normal | #5 |
| schiff immunohistochemical | #5 |
| allergic conjunctiva conjunctivitis | #5 |
| severity akc | #5 |
| hel akc | #5 |
| warmer applied | #5 |
| impression cytology samples | #5 |
| crth2 eosinophils | #5 |
| 376±56 years | #5 |
| endophthalmitis eosinophils | #5 |
| regulation benzamidines | #6 |
| diseases periostin | #6 |
| challenge cac | #6 |
| betamethasone oral | #6 |
| female fluorometholone | #6 |
| upper tarsal conjunctiva | #6 |
| dermatitis scored | #6 |
| tears xerophthalmia | #6 |
| syndrome tablets | #6 |
| signs scored | #6 |
| grading tear | #6 |
| solution commercial | #6 |
| symptoms vkc | #6 |
| noninvasive suction device | #6 |
| allergic diathesis | #6 |
| edema severity | #6 |
| eyes atopic | #6 |
| conjunctival brush cytology | #6 |
| tear stability values | #6 |
| rate tbut | #6 |
| coated elf | #6 |
| strip meniscometry scores | #6 |
| remodeling vkc | #6 |
| ointment blood | #6 |
| sac vkc | #6 |
| eye evaluated | #6 |
| extract sterilized | #6 |
| functions topical | #6 |
| treatment postoperative inflammation | #6 |
| rtpcr epithelial cells | #6 |
| pathogenesis ocular | #6 |
| tacrolimus chronic | #6 |
| tear meniscus patients | #6 |
| testing tear | #6 |
| defect penetrating | #6 |
| topical cys | #6 |
| fluorometholone follow | #6 |
| conjunctival diseases | #6 |
| severe vkc | #6 |
| tbut vital | #6 |
| cgvhd improvements | #6 |
| cyclosporine 01 | #6 |
| schirmer1 test values | #6 |
| chloride eye | #6 |
| tears acinar | #6 |
| patients visante | #6 |
| ade sde | #6 |
| fva landolt | #6 |
| allergens cedrus | #6 |
| cys ocular | #6 |
| papillae mucous | #6 |
| antiallergic eye | #6 |
| atopic eyelids | #6 |
| controlling eyelid | #6 |
| pcr muc5ac | #6 |
| induced tear | #6 |
| dfna | #6 |
| july correlation | #6 |
| elasticity cutometer | #6 |
| conjunctivitis sac | #6 |
| 20 pbs | #6 |
| levocabastine effective | #6 |
| corneal fibroblasts pathogenesis | #6 |
| instability conjunctival | #6 |
| eosinophils crth2 | #6 |
| il4 il2r | #6 |
| agents interferometry | #6 |
| obstructive mgd patients | #6 |
| evaporation vital | #6 |
| tryptase proliferation | #6 |
| rose bengal dyes | #6 |
| itching conjunctival | #6 |
| akc vernal keratoconjunctivitis | #6 |
| eosinophil recruiting chemokines | #6 |
| elevation refractory | #6 |
| concomitant eye | #6 |
| oxidation hel | #6 |
| 4 9 genes | #6 |
| dressings female | #6 |
| bengal vital stainings | #6 |
| scores goblet | #6 |
| hyperemia swelling | #6 |
| ocular surface findings | #6 |
| akc refractory | #6 |
| treatment tacrolimus | #6 |
| sde ade | #6 |
| allergic conjunctivitis cac | #6 |
| levels air pollutants | #6 |
| dust asian | #6 |
| severe stevens | #6 |
| findings dry eye | #6 |
| tear eosinophil | #6 |
| twicedaily instillation | #6 |
| tranilast inhibition | #6 |
| examinations tear | #6 |
| ocular fatigue | #6 |
| topical cys treatment | #6 |
| patients seldi | #6 |
| samples underwent | #6 |
| conjunctival confocal | #6 |
| density conjunctival | #6 |
| hyperemia imidazoles | #6 |
| inflammatory cell densities | #6 |
| ecp markers | #6 |
| differences tear | #6 |
| severe ocular inflammation | #6 |
| 4 muc | #6 |
| specimens akc | #6 |
| intolerable irritation | #6 |
| severe vernal | #6 |
| fibroblasts conjunctival | #6 |
| defect ped | #6 |
| topical levocabastine | #6 |
| tear ecp | #6 |
| corneal damage | #6 |
| corneal temperature | #6 |
| suspension 01 | #7 |
| increases proliferative | #7 |
| sensation symptom | #7 |
| mucins periodic | #7 |
| mucins tears | #7 |
| status atopic | #7 |
| eyelid surface | #7 |
| solution bf | #7 |
| conjunctivitis risk | #7 |
| ulcer corneal | #7 |
| western blotting nfκb | #7 |
| crth2 normal | #7 |
| steroidal benzophenones | #7 |
| ulcers revealed | #7 |
| key prostaglandin | #7 |
| accommodating intraocular lens | #7 |
| tacrolimus topical steroids | #7 |
| meniscometry testing | #7 |
| cases preventing | #7 |
| superiority placebo | #7 |
| hyperemia adverse | #7 |
| evaluation eyelid | #7 |
| eczema frequently | #7 |
| allergic eyelid | #7 |
| pgd2 dependent | #7 |
| 0001 impression | #7 |
| tears th2 | #7 |
| silicone plugs | #7 |
| neutrophils corneal | #7 |
| attendance allergic | #7 |
| pathogenesis subsequent | #7 |
| cytology differ | #7 |
| prostaglandin atopic | #7 |
| thought pathogenesis | #7 |
| severe persistent cases | #7 |
| alpha tears | #7 |
| conclusion mmc | #7 |
| tear supply | #7 |
| tears alpha | #7 |
| conjunctival brush | #7 |
| amniotic membrane patching | #7 |
| allergic dna | #7 |
| conjunctival inflammatory | #7 |
| sources chemokines | #7 |
| vkc gpc | #7 |
| eyes ophthalmologists | #7 |
| pge2 cox2 levels | #7 |
| papillae formation | #7 |
| development allergic conjunctivitis | #7 |
| ulceration healthy | #7 |
| mmc 005 | #7 |
| incidence meibomian | #7 |
| collected brush | #7 |
| tmh measurements | #7 |
| administration fluorescein | #7 |
| corneal lesion | #7 |
| mmc observed | #7 |
| inhibitor ono2235 | #7 |
| injection oedema | #7 |
| examination tear | #7 |
| normal blinking | #7 |
| chemotaxis eosinophils | #7 |
| surgery cooling | #7 |
| improvements symptom scores | #7 |
| nonparametric tears | #7 |
| necrotizing anterior | #7 |
| ocular inflammatory disorder | #7 |
| gpc vkc | #7 |
| conjunctivitis dry | #7 |
| 10 clinical signs | #7 |
| patients comfort level | #7 |
| sensitization asian | #7 |
| revealed eosinophils | #7 |
| age 325 years | #7 |
| hrtii rcm | #7 |
| conjunctival complications | #7 |
| 4 tear | #7 |
| tacrolimustreated eyes | #7 |
| conjunctiva brush | #7 |
| procedures radioimmunoassay | #7 |
| rose bengal fluorescein | #7 |
| concentrations conjunctival | #7 |
| adult blepharitis | #7 |
| nerves tear | #7 |
| tnfalpha eosinophils | #8 |
| asia cats | #8 |
| infrared radiation thermometry | #8 |
| limbalbased conjunctival flap | #8 |
| ulcers detected | #8 |
| graticule scale | #8 |
| akc subjects | #8 |
| trabeculectomy amniotic | #8 |
| pathogenesis test | #8 |
| age 170 ± | #8 |
| radiation thermography | #8 |
| rollable intraocular | #8 |
| teros | #8 |
| ihc hel | #8 |
| teros values | #8 |
| controls seldi | #8 |
| ccl5 conjunctiva | #8 |
| oedema scores | #8 |
| correlation vital | #8 |
| chemotaxis pgd2 | #8 |
| transient burning sensation | #8 |
| patients corneal | #8 |
| corneal fibroblasts tnfalpha | #8 |
| alterations cornea | #8 |
| allergic dibenzazepines | #8 |
| flare counts | #8 |
| palpebral bulbar | #8 |
| conjunctival findings | #8 |
| fva measurements | #8 |
| brush cytology | #8 |
| controls brush | #8 |
| stainings schirmer | #8 |
| 006 degree | #8 |
| corneal ulcer | #8 |
| occlusion lacrimal | #8 |
| blink patients | #8 |
| blinking body | #8 |
| fluorescein rose bengal | #8 |
| par2 mast cells | #8 |
| 4 chemokines | #8 |
| eye redness | #8 |
| mitomycin post | #8 |
| underwent tear | #8 |
| pollen odds | #8 |
| corneal epithelial lesions | #8 |
| meniscometry tear | #8 |
| staining hel | #8 |
| conjunctivitis eyes | #8 |
| microscopy conjunctival | #8 |
| meniscometry scores | #8 |
| values slit | #8 |
| itching hyperemia | #8 |
| akc patients controls | #8 |
| sac akc | #8 |
| noninfectious corneal | #8 |
| keratocytes cytokines | #8 |
| hoc analysis study | #8 |
| surface teros | #8 |
| definite dry eye | #8 |
| techniques keratoconjunctivitis | #8 |
| patients vkc | #8 |
| stained hel | #8 |
| alterations allergic | #8 |
| superficial cells groups | #8 |
| classified allergic | #8 |
| il4 enzyme | #8 |
| blinking desiccation | #8 |
| betamethasone calcineurin | #8 |
| scores teros | #8 |
| induced intraocular | #8 |
| conjunctival sensation | #8 |
| corneal scores | #8 |
| expressions thought | #8 |
| diameter acinar | #8 |
| diagnosis conjunctivitis | #9 |
| pretreatment docosahexaenoic | #9 |
| vital stainings | #9 |
| fatigue dry | #9 |
| sensitivity confocal | #9 |
| glaucoma younger age | #9 |
| sensitivity conjunctival | #9 |
| shield ulcers | #9 |
| wash solution | #9 |
| histocytological study | #9 |
| prevalence vkc | #9 |
| prevalence weather | #9 |
| level pollutants | #9 |
| concentration tears | #9 |
| vital staining scores | #9 |
| differ allergic | #9 |
| excision intraoperative | #9 |
| foreign body sensation | #9 |
| cases conjunctivitis | #9 |
| supply superior | #9 |
| tnfalpha fibroblasts | #9 |
| eye normal subjects | #9 |
| clinical ocular findings | #9 |
| blood level tacrolimus | #9 |
| conjunctival fibroblast | #9 |
| reductase cataract | #9 |
| prospective study tacrolimus | #9 |
| design eyelid | #9 |
| patients tacrolimus treatment | #9 |
| elisa tears | #9 |
| mmc recurrence | #9 |
| tacrolimus treating | #9 |
| injection edema | #9 |
| hel 4 | #9 |
| severity corneal | #9 |
| subjective ocular | #9 |
| tacrolimus 95 | #9 |
| 0001 schirmer | #9 |
| measurements vital | #9 |
| acid goblet | #9 |
| eye grade | #9 |
| untreated asian | #9 |
| conjunctivitis cases | #9 |
| specular microscopic evaluation | #9 |
| ono2235 | #9 |
| implantation 1cu | #9 |
| smart eye | #9 |
| fluorescein rose | #9 |
| observed obstructive | #9 |
| operatedon eye | #9 |
| tears thermography | #9 |
| crth2 expression eosinophils | #9 |
| diseases conjunctivitis | #9 |
| inflammation steroidal | #9 |
| cobblestone papillae | #9 |
| hyperemia iop | #9 |
| tear level | #9 |
| pathogen allergic | #9 |
| stress staining | #9 |
| pollution conjunctivitis | #9 |
| pilocarpine tablets | #9 |
| cys eye | #9 |
| superior limbic | #9 |
| genes cxc | #9 |
| sufficient examination | #9 |
| received preserved | #9 |
| symptoms allergic conjunctivitis | #9 |
| sio2 pbs | #9 |
| par2 mast | #10 |
| icam1 tnfalpha | #10 |
| evaluation atopic | #10 |
| complain | #10 |
| eye clinically | #10 |
| drugs conjunctival | #10 |
| conjunctival edema | #10 |
| chemokines cxc chemokines | #10 |
| conjunctivitis spring | #10 |
| conjunctivitis atopic | #10 |
| diagnosis dry eye | #10 |
| measuring tear | #10 |
| central graft | #10 |
| eye infrared | #10 |
| total tear ige | #10 |
| levels tears | #10 |
| cornea eosinophils | #10 |
| staining oral | #10 |
| nonallergic conjunctivitis | #10 |
| underwent slit | #10 |
| bengal stainings | #10 |
| topical cyclosporine patients | #10 |
| status conjunctival | #10 |
| humans mucin | #10 |
| crth2 chemotaxis | #10 |
| conjunctivitis histamine | #10 |
| patients ulcers | #10 |
| visante optical | #10 |
| produced conjunctival | #10 |
| cytometry il4 | #10 |
| lower tmh | #10 |
| eye surface | #10 |
| humans conjunctival | #10 |
| layer alterations | #10 |
| staining brush | #10 |
| compared eyes | #10 |
| ophthalmic adolescent | #10 |
| vmr values | #10 |
| conjunctivitis japan | #10 |
| punctal occlusion | #10 |
| allergic ocular | #10 |
| incubated il4 | #10 |
| sensation ocular | #10 |
| subbasal stromal | #10 |
| substance tears | #10 |
| measurement strip | #10 |
| insufficient local | #10 |
| shield ulcer | #10 |
| laminin actins | #10 |
| muc5ac muc16 | #10 |
| allergic bronchitis | #10 |
| aged conjunctivitis | #10 |
| assessed conjunctival | #10 |
| meibomian gland obstruction | #10 |
| allergic conjunctivitis spring | #10 |
| iop hyperemia | #10 |
| scale tear | #10 |
| lacrimal puncta | #10 |
| leupeptin benzamidine | #10 |
| tears 10 | #10 |
| proliferation conjunctival | #10 |
| muc16 muc5ac | #10 |
| functions dry | #10 |
| tear cytology | #10 |
| improvement tear | #10 |
| treatment vkc | #10 |
| resection regrowth | #10 |
| disease edition | #11 |
| surgery 13 eyes | #11 |
| antivcaigg | #11 |
| schirmer1 test | #11 |
| vkc adolescent | #11 |
| count conjunctivitis | #11 |
| tears conjunctival | #11 |
| palpebral bulbar conjunctiva | #11 |
| amniotic membrane patch | #11 |
| methods conjunctival | #11 |
| elisa il4 | #11 |
| vcam1 tnfalpha | #11 |
| diagnosis allergic | #11 |
| common conjunctival | #11 |
| cooling operation | #11 |
| keratitis observed | #11 |
| vernal | #11 |
| anesthesia strabismus | #11 |
| test tear | #11 |
| drop artificial | #11 |
| function ocular | #11 |
| elasticity treatment | #11 |
| association outpatient | #11 |
| prevalence dry eye | #11 |
| hel hne | #11 |
| ophthalmic solution | #11 |
| purpose metaplasia | #11 |
| vkc | #11 |
| preserved artificial | #11 |
| eosinophils prostaglandin | #11 |
| vkc normal | #11 |
| interleukin4 male | #11 |
| smart eye camera | #11 |
| coherence dry | #11 |
| cytometry oligonucleotide | #11 |
| landolt visual | #11 |
| patient atopic | #11 |
| 1 month reduction | #11 |
| lamp microscope | #11 |
| fibroblasts pathogenesis | #11 |
| weeks papillary | #11 |
| higher muc1 | #11 |
| matched dry | #11 |
| elicited statistically | #11 |
| sensation staining | #11 |
| levocabastine hydrochloride | #11 |
| genes corneal | #11 |
| vmr fva | #11 |
| initiation tacrolimus | #11 |
| sensation tear | #11 |
| therapy conjunctivitis | #11 |
| patients sac | #12 |
| 1cu iol | #12 |
| selected severity | #12 |
| density muc5ac | #12 |
| projects tears | #12 |
| 002 ophthalmic | #12 |
| density acinar | #12 |
| conventional slit | #12 |
| pemirolast potassium | #12 |
| tears conjunctivitis | #12 |
| fva visual | #12 |
| ulcers squamous | #12 |
| 1cu accommodating | #12 |
| fluorescein scores | #12 |
| receptor crth2 | #12 |
| leupeptins mast | #12 |
| radiography tears | #12 |
| appearance atopic | #12 |
| expression 8 genes | #12 |
| drugs pge2 | #12 |
| corneal shield | #12 |
| ccl11 conjunctiva | #12 |
| eye diagnosed | #12 |
| microscopy efficient | #12 |
| corneal aesthesiometry | #12 |
| cornea density | #12 |
| mmhg elevation | #12 |
| acids chemokine | #12 |
| mgd controls | #12 |
| specimens eyes | #12 |
| immunologic rejection | #12 |
| surface diabetic | #12 |
| levocabastine patients | #12 |
| keratoconjunctivitis patients | #12 |
| findings conjunctival | #12 |
| fva vmr | #12 |
| extracts pollens | #12 |
| conjunctival injection | #12 |
| severe binocular | #12 |
| keratoplasty glaucoma | #12 |
| controls antibody titers | #12 |
| biomarker allergic | #12 |
| supratarsal injection | #12 |
| iop glucocorticoids humans | #12 |
| 001 specimens | #12 |
| 1821 subjects | #12 |
| dermatitis tacrolimus | #12 |
| damage height | #12 |
| lacrimal punctal | #12 |
| highspeed highresolution | #12 |
| coated lactoferrin | #12 |
| iop younger | #12 |
| tear hel | #13 |
| temperature cataract | #13 |
| improvement vital | #13 |
| thirty eyes | #13 |
| stability vital | #13 |
| week corneal | #13 |
| topical cyclosporine treatment | #13 |
| anterior segment photography | #13 |
| months healed | #13 |
| upper tarsal | #13 |
| glaucoma keratoplasty | #13 |
| ulcers corneal | #13 |
| schirmers test values | #13 |
| bengal fluorescein | #13 |
| aged disposable | #13 |
| applied operation | #13 |
| epithelial disease | #13 |
| treatment allergic conjunctivitis | #13 |
| vmr measurements | #13 |
| time fluorescein | #13 |
| called giant | #13 |
| compared postsurgical | #13 |
| inflammation tear | #13 |
| cell flare | #13 |
| conjunctival oedema | #13 |
| syndrome reactivation | #13 |
| fluorometholone fml | #13 |
| tear functions | #13 |
| chemokines stimulation | #13 |
| objective signs | #13 |
| symptoms conjunctival | #13 |
| dry eye examination | #13 |
| conclusions ocular | #13 |
| japan keratoconjunctivitis | #13 |
| keratocytes incubated | #13 |
| interferometry tear | #13 |
| specimens levels | #13 |
| papillary samples | #13 |
| remodeling relevant | #13 |
| sd105 | #13 |
| glaucoma younger | #13 |
| corneal complications | #13 |
| blood levels tacrolimus | #13 |
| 5ac ophthalmic | #13 |
| suspensions tacrolimus | #13 |
| outcomes 01 | #13 |
| scraped samples | #13 |
| protein conjunctival | #13 |
| coherence viscosupplements | #13 |
| occlusion dry | #14 |
| dry eye controls | #14 |
| secrete mediators | #14 |
| proliferative lesion | #14 |
| fungi adolescent | #14 |
| radioimmunoassay tears | #14 |
| epithelial muc5ac | #14 |
| mcfg treatment | #14 |
| visits allergic | #14 |
| factors conjunctivitis | #14 |
| conjunctival impression | #14 |
| cornea endophthalmitis | #14 |
| functions corneal | #14 |
| eyes 002 | #14 |
| test rose | #14 |
| solutions retrospective | #14 |
| fibroblast damage | #14 |
| 14 flare | #14 |
| conjunctivitis vernal | #14 |
| vehicle eye | #14 |
| clinically allergic | #14 |
| density tear | #14 |
| fluorometholone humans | #14 |
| flare count | #14 |
| higher allergic | #14 |
| bf 01 | #14 |
| pilocarpine effective | #14 |
| conjunctival muc5ac | #14 |
| benzamidines blotting | #14 |
| blinking patients | #14 |
| conjunctival allergen challenge | #14 |
| conjunctivitis background | #14 |
| schirmer1 | #14 |
| clinical corneal | #14 |
| tranilast anti | #15 |
| steroidal cornea | #15 |
| ocular surface mucins | #15 |
| receptor pgd2 | #15 |
| giant papillary | #15 |
| examined existence | #15 |
| topical 01 | #15 |
| mucous discharge | #15 |
| damaged fibroblasts | #15 |
| monitoring tear | #15 |
| adherence fibroblasts | #15 |
| eye drop treatment | #15 |
| ige ecp | #15 |
| effects benzalkonium | #15 |
| ulcer echinocandins | #15 |
| investigated corneal | #15 |
| tmh values | #15 |
| complications height | #15 |
| patients vernal | #15 |
| surface vital | #15 |
| rtpcr cytometry | #15 |
| superior conjunctiva | #15 |
| olopatadine 01 | #15 |
| corneal recurrence | #15 |
| analysis par2 | #15 |
| day bf | #15 |
| vkc methods | #15 |
| cytology brush | #15 |
| ophthalmology tokyo | #15 |
| bromobenzenes child | #15 |
| complications mmc | #15 |
| basal tear secretion | #15 |
| evaluation conjunctival | #15 |
| occlusion rose | #15 |
| blepharitis conjunctivitis | #15 |
| diseases 2020 | #15 |
| correlation tear | #15 |
| improvement corneal | #15 |
| mmc female follow | #15 |
| ocular acrylic | #15 |
| firstline drug | #15 |
| occlusion oct | #15 |
| irritation scores | #15 |
| improvement subjective symptoms | #15 |
| ocular itching | #15 |
| bilateral conjunctivitis | #15 |
| agents blepharitis | #15 |
| expression realtime pcr | #15 |
| lacrimation | #16 |
| ulcers positive | #16 |
| measurements tear | #16 |
| female goblet | #16 |
| dust allergic | #16 |
| treatment eyelid | #16 |
| eosinophils receptor | #16 |
| 2 conjunctival | #16 |
| reduction goblet | #16 |
| odds ratio remission | #16 |
| safety 01 | #16 |
| hours visit | #16 |
| ari administration | #16 |
| assessment conjunctival | #16 |
| ige correlation | #16 |
| controls papillary | #16 |
| alpha ortho | #16 |
| segment photography | #16 |
| fungi odds | #16 |
| total clinical scores | #16 |
| patients vernal keratoconjunctivitis | #16 |
| temperature conjunctiva | #16 |
| objective ocular | #16 |
| inhibitor ari | #17 |
| initiation objective | #17 |
| analyzed 005 | #17 |
| ceramide gel | #17 |
| increased goblet cells | #17 |
| evaluation inflammatory | #17 |
| betamethasone induced | #17 |
| fibroblasts damaged | #17 |
| eyes schirmer | #17 |
| inflammation blotting | #17 |
| signs ded | #17 |
| staining muc1 | #17 |
| age dry | #17 |
| agents cedrus | #17 |
| sclera trabeculectomy | #17 |
| 13 females age | #17 |
| conjunctival samples | #17 |
| expression eotaxin1 | #17 |
| warmer treatment | #17 |
| 20 normal patients | #17 |
| ocular allergic inflammation | #17 |
| fibroblasts mcp1 | #17 |
| corneal sensation | #17 |
| wear soft | #17 |
| meniscometry | #17 |
| clearance corneal | #17 |
| strip meniscometry | #17 |
| muc16 mrna | #17 |
| drops eyes | #17 |
| decrease ocular | #18 |
| 30 ige | #18 |
| higher tears | #18 |
| induce corneal | #18 |
| differentiation inflammatory cells | #18 |
| correlation clinical signs | #18 |
| tear evaporation rate | #18 |
| lower eyes | #18 |
| intraoperative 002 | #18 |
| technique glaucoma | #18 |
| inflammation lenses | #18 |
| trabeculectomy glaucoma | #18 |
| ocular surface status | #18 |
| tear function | #18 |
| cytology corneal | #18 |
| studies rose | #18 |
| ulceration subjects | #18 |
| evaluation tear | #18 |
| ulcers compared | #18 |
| tnfα inflammatory response | #18 |
| obstructive dysfunction | #18 |
| rantes response | #18 |
| noncl wearers | #18 |
| pollen fungi | #18 |
| test tears | #18 |
| fibroblasts giant | #18 |
| types dry eye | #18 |
| groups spt | #18 |
| conclusion ocular | #18 |
| complete staining | #18 |
| associations level | #18 |
| concentrations corneal | #18 |
| dibenzazepines dibenzoxepins | #18 |
| cd45 inflammatory | #18 |
| bengal sjogren | #18 |
| cytology decrease | #18 |
| male ophthalmic solutions | #18 |
| prospective study eyes | #19 |
| beta1 il1beta | #19 |
| operation applied | #19 |
| periostin biomarker | #19 |
| steroid female | #19 |
| seldi analysis | #19 |
| early efficacy | #19 |
| 3 severe | #19 |
| evaluated infrared | #19 |
| dha pretreatment | #19 |
| 1151 years | #19 |
| subjects underwent | #19 |
| conjunctivitis topical | #19 |
| inflammatory cells patients | #19 |
| seldi proteinchip | #19 |
| aged ophthalmic | #19 |
| temperature artificial | #19 |
| eosinophils adhered | #19 |
| mitomycin ophthalmologic | #19 |
| vernal keratoconjunctivitis | #19 |
| aged cautery | #19 |
| ige tear | #19 |
| staining scores | #19 |
| effective tacrolimus | #19 |
| sodium 01 | #19 |
| sma performed | #19 |
| outpatient attendance | #19 |
| microscopy scans | #19 |
| measurements visante | #19 |
| total signs | #19 |
| limbal allograft | #19 |
| human conjunctival | #19 |
| pollen association | #20 |
| persistent epithelial defect | #20 |
| allergic female humans | #20 |
| lower dry | #20 |
| proteins tears | #20 |
| cytology upper | #20 |
| ulcers cell | #20 |
| explain pathogenesis | #20 |
| treated 01 | #20 |
| height tmh | #20 |
| conclusion tacrolimus | #20 |
| symptoms allergic | #20 |
| mucin alterations | #20 |
| echinocandins eye | #20 |
| corneal impression | #20 |
| bilateral agerelated cataract | #20 |
| tears corneal | #20 |
| vernal keratoconjunctivitis vkc | #20 |
| surface findings | #20 |
| summarized based | #20 |
| plaques graded | #20 |
| improvements ocular | #20 |
| evaluate noninferiority | #20 |
| patients strip | #20 |
| xerophthalmia adolescent | #20 |
| decreased conjunctival | #20 |
| 022 pg | #20 |
| conjunctivitis primary | #20 |
| conjunctivitis caused | #20 |
| common ocular disorders | #20 |
| methane nonmethane hydrocarbons | #21 |
| induced topical | #21 |
| eye smaller | #21 |
| ige groups | #21 |
| peripheral blood eosinophils | #21 |
| conclusions topical | #21 |
| adhesion fibroblast | #21 |
| preventing corneal | #21 |
| keratoconjunctivitis atopic | #21 |
| microscopy patients | #21 |
| acuity assessment | #21 |
| cultured conjunctiva | #21 |
| radiation thermometer | #21 |
| levels hel | #21 |
| fluorescence postoperative | #21 |
| film lipid | #21 |
| symptoms include | #21 |
| patients concomitant treatment | #21 |
| conjunctiva role | #21 |
| reduction topical | #21 |
| patients cedar | #21 |
| lipid oxidative | #21 |
| ocular symptoms signs | #21 |
| surface mucin | #21 |
| eosinophils flow cytometry | #21 |
| eye control | #21 |
| tears blood | #21 |
| cornea clinical | #21 |
| crth2 expressed | #21 |
| reaction tears | #21 |
| therapies allergic | #22 |
| epithelial lipid | #22 |
| eyes nerve | #22 |
| 005 topical | #22 |
| flare anterior | #22 |
| correlation humidity | #22 |
| fibroblasts anti | #22 |
| fluorescein staining | #22 |
| mgd adult | #22 |
| muc5ac patients | #22 |
| accommodation amplitude | #22 |
| negative lower | #22 |
| haze photorefractive | #22 |
| serum periostin patients | #22 |
| types ocular | #22 |
| 01 tacrolimus | #22 |
| lamp examinations | #23 |
| diseases diclofenac | #23 |
| preschool conjunctivitis | #23 |
| disease atopic | #23 |
| 215 ± | #23 |
| tear dynamics | #23 |
| score deqs | #23 |
| prospectively surgery | #23 |
| subjects squamous | #23 |
| solution compared | #23 |
| cooling applied | #23 |
| patients topical steroids | #23 |
| palpebral conjunctiva | #23 |
| 01 severe | #23 |
| blood concentration tacrolimus | #23 |
| hrt confocal | #23 |
| corneal fluorescein | #23 |
| tests adenovirus | #23 |
| function mucin | #23 |
| layer interferometry | #23 |
| solution corneal | #23 |
| 5 females | #23 |
| il4 tnf | #23 |
| labeling tears | #23 |
| pge2 supernatants | #23 |
| vkc patients | #24 |
| 27yearold male patient | #24 |
| edema drug | #24 |
| signs serum | #24 |
| cell meter | #24 |
| histamine development | #24 |
| samples conjunctival | #24 |
| formation allergic | #24 |
| fungal corneal | #24 |
| patients tacrolimus ointment | #24 |
| control tear | #24 |
| surface tear | #24 |
| tarsal conjunctiva | #24 |
| ocular allergies | #24 |
| warming device | #24 |
| conjunctiva diabetes | #24 |
| bengal tears | #24 |
| interleukin4 oligonucleotide | #24 |
| layer tear | #24 |
| vital staining | #24 |
| diseases web | #24 |
| tokyo dental | #24 |
| local allergic reaction | #24 |
| dermatitis improved | #24 |
| slitlamp examinations | #25 |
| atopic eosinophils humans | #25 |
| confocal prospective | #25 |
| eyes epithelial | #25 |
| staining goblet | #25 |
| vkc compared | #25 |
| level tears | #25 |
| antigen conjunctiva | #25 |
| patients atopic diseases | #25 |
| bengal scores | #25 |
| schedule eosinophil | #25 |
| 0001 dry | #25 |
| dynamics tear | #25 |
| corneal plaques | #25 |
| rtpcr rsv | #25 |
| vcam1 activated | #25 |
| superficial cells | #25 |
| rsv rtpcr | #25 |
| density squamous | #25 |
| protein rtpcr | #25 |
| steroid eye | #25 |
| conjunctival inflammation | #26 |
| postkeratoplasty glaucoma | #26 |
| slit lamp examinations | #26 |
| lnfs | #26 |
| level il4 | #26 |
| keratoconjunctivitis caused | #26 |
| 100 nylon | #26 |
| solutions corneal | #26 |
| wheal diameter | #26 |
| actins collagen | #26 |
| correlated corneal | #26 |
| conclusions improvement | #26 |
| 005 immunoreactive | #26 |
| smallincision cataract surgery | #26 |
| dmem f12 medium | #26 |
| conjunctivitis | #26 |
| singletreatment groups | #26 |
| specific ige positivity | #26 |
| symptoms itching | #26 |
| statistical decrease | #26 |
| treatment meibomian | #26 |
| damage adhesion | #26 |
| human α defensin | #26 |
| subjects measuring | #26 |
| tbut tear | #26 |
| rapid epithelialization | #26 |
| corneal ulcers | #26 |
| 01 topical | #26 |
| diseases ambient | #26 |
| eyes topical | #26 |
| aureus detected | #26 |
| adhered fibroblasts | #26 |
| acinar unit | #26 |
| 005 symptoms | #27 |
| cytometry chemotaxis | #27 |
| 01 cyclosporine | #27 |
| epinastine | #27 |
| conjunctival epithelial | #27 |
| lymphocytes specimens | #27 |
| tear ocular | #27 |
| reaction sensation | #27 |
| child cytological | #27 |
| eosinophils fibroblasts | #27 |
| alpha eosinophils | #27 |
| interleukin4 polymerase | #27 |
| oct prospective | #27 |
| prescribed topical | #27 |
| factor exacerbation | #27 |
| antibodies brush | #27 |
| density subbasal | #27 |
| therapy conjunctiva | #27 |
| associations prevalence | #27 |
| prevalence allergic diseases | #28 |
| provide relief | #28 |
| conjunctiva dexamethasone | #28 |
| solutions ophthalmologic | #28 |
| 4 5ac | #28 |
| conjunctival epithelial cells | #28 |
| stress atopic | #28 |
| assay eosinophils | #28 |
| il13 il1beta | #28 |
| ophthalmic | #28 |
| objective scores | #28 |
| corneal vivo | #28 |
| diseases proliferative | #28 |
| giant papillae | #28 |
| underwent immunohistochemical | #28 |
| 2 iol | #28 |
| eosinophil adherence | #28 |
| assessment tear | #28 |
| corneal ulceration | #28 |
| papillae patients | #28 |
| severe ocular | #28 |
| chemotactic activity eosinophils | #28 |
| studies conjunctivitis | #29 |
| numbers inflammatory | #29 |
| rosebengal | #29 |
| scores schirmer | #29 |
| 5ac mucins | #29 |
| aged thermography | #29 |
| sac compared | #29 |
| allergic regulation | #29 |
| cys treatment | #29 |
| thermography adolescent | #29 |
| inhibited tranilast | #29 |
| ketotifen fumarate | #29 |
| performed morphometric | #29 |
| eye mask | #29 |
| flare cell | #29 |
| corneal conjunctival | #29 |
| disease periostin | #29 |
| conjunctiva dose | #29 |
| minutes visit | #30 |
| regrowth observed | #30 |
| infection conjunctival | #30 |
| palpebral | #30 |
| dermatitis efficacy | #30 |
| fibroblasts protease | #30 |
| expressed crth2 | #30 |
| conjunctivitis humans | #30 |
| effective artificial | #30 |
| atopic diagnostic | #30 |
| common adverse reaction | #30 |
| mucins ophthalmic | #30 |
| redness eye | #30 |
| specificity tears | #30 |
| symptoms accompanying | #30 |
| il2r serum | #30 |
| recruitment day | #30 |
| tear serum | #30 |
| conjunctivitis patients | #30 |
| eye common | #30 |
| inhibitors pollen | #30 |
| ocular surface alterations | #30 |
| tear ige | #30 |
| conjunctiva cells | #30 |
| syndromes equipment | #30 |
| vegf cultured | #31 |
| combinations eosinophils | #31 |
| dermatitis purpose | #31 |
| meibomian gland secretion | #31 |
| ige negative | #31 |
| worse observed | #31 |
| pathogenesis corneal | #31 |
| properties tears | #31 |
| acuity fva | #31 |
| schirmer scores | #31 |
| hel levels | #31 |
| neutrophils severity | #31 |
| disease summarized | #31 |
| atopic 10 | #31 |
| inflammation atopic | #31 |
| levels july | #31 |
| fibroblasts pcr | #31 |
| epithelial mucins | #31 |
| scores corneal | #31 |
| expressed eosinophils | #31 |
| substantial interrater agreement | #32 |
| expressibility | #32 |
| conjunctival cells | #32 |
| diagnosed dry | #32 |
| reduced steroid | #32 |
| limbus cornea | #32 |
| sign scores | #32 |
| western blotting effects | #32 |
| signs improved | #32 |
| tear meniscus height | #32 |
| tgfbeta1 il1beta | #32 |
| deqs | #32 |
| schirmer test values | #32 |
| analysis tears | #32 |
| keratoconjunctivitis | #32 |
| eye sjögren | #32 |
| prostaglandin cell | #32 |
| count prostaglandin | #33 |
| ige histamine | #33 |
| atopic skin disease | #33 |
| allergic double | #33 |
| levocabastine | #33 |
| signs evaluated | #33 |
| edema correlated | #33 |
| seasonal young | #33 |
| film break | #33 |
| 4 grades | #33 |
| immunoglobulin interferometry | #33 |
| conclusions confocal | #33 |
| haze score | #33 |
| muc 1 | #33 |
| numbers quantitative | #33 |
| iop induced | #33 |
| visante | #33 |
| treatment mgd | #34 |
| intraocular pressure surgery | #34 |
| fluorometholone glucocorticoids | #34 |
| conjunctiva cytokines | #34 |
| il1beta tgfbeta1 | #34 |
| 10 objective | #34 |
| bengal staining | #34 |
| proteinchip array | #34 |
| eyes corneal | #34 |
| fibroblasts purpose | #34 |
| clinical signs patients | #34 |
| therapy histamine | #34 |
| 01 effective | #34 |
| eye 10 | #34 |
| alpha fibroblasts | #34 |
| objective symptoms | #35 |
| cyclosporine cys | #35 |
| mucins prospective | #35 |
| hypertension tacrolimus | #35 |
| eye 20 | #35 |
| virus capsid antigen | #35 |
| tear stability | #35 |
| adult asthenopia | #35 |
| interrater reproducibility | #35 |
| 6 months conclusion | #35 |
| anterior scleritis | #36 |
| efficacy groups | #36 |
| measured tear | #36 |
| tear clearance | #36 |
| humans keratoconjunctivitis | #36 |
| severe allergic | #36 |
| differential dry | #36 |
| vdt users | #36 |
| eyes acrysof | #36 |
| resection 005 | #36 |
| tear samples | #36 |
| ocular surface inflammation | #36 |
| schirmer 1 | #36 |
| functional visual acuity | #36 |
| diseases eosinophil | #36 |
| recurrence corneal | #37 |
| conducted compliance | #37 |
| tenon anesthesia | #37 |
| tears tumor | #37 |
| wellrecognized risk | #37 |
| eyelid skin | #37 |
| schirmer 1 test | #37 |
| tacrolimus 12 | #37 |
| contact lens surface | #37 |
| scleritis episcleritis | #37 |
| delefilcon | #37 |
| 002 mmc | #37 |
| induced iop | #37 |
| laser flarecell meter | #37 |
| oct effective | #37 |
| phacoemulsification implantation | #38 |
| cac japanese | #38 |
| post cataract | #38 |
| device eye | #38 |
| gland lipid | #38 |
| allergic cromolyn | #38 |
| pemirolast | #38 |
| aged olopatadine | #38 |
| 002 mitomycin | #38 |
| exhibited correlation | #38 |
| cyclosporine dry | #39 |
| tears eye | #39 |
| degree 20 | #39 |
| solutions patient | #39 |
| infiltration corneal | #39 |
| accommodating intraocular | #39 |
| 0001 specimens | #39 |
| 005 oct | #39 |
| cells conjunctiva | #39 |
| patients dry eye | #39 |
| response pretreatment | #39 |
| conjunctiva limbus | #39 |
| tests diagnostic accuracy | #39 |
| atopic dry | #39 |
| pharmacology clinical efficacy | #40 |
| subjects specimens | #40 |
| eye patients | #40 |
| samples eyes | #40 |
| decreased inflammation | #40 |
| biomarkers conjunctiva | #40 |
| drops corneal | #40 |
| acid chemokine | #40 |
| tmh | #40 |
| ulcers control | #40 |
| endothelial rejection | #40 |
| treated topical | #41 |
| homologous visual | #41 |
| conjunctivitis gpc | #41 |
| epitheliopathy | #41 |
| eyes superior | #41 |
| il1beta vegf | #41 |
| pollution severe | #41 |
| vegf il1beta | #41 |
| stimulate vascular | #41 |
| treatment dry | #41 |
| α pge2 | #41 |
| ecp concentrations | #41 |
| efficient noninvasive | #42 |
| october july | #42 |
| allergens conjunctivitis | #42 |
| scans underwent | #42 |
| break time | #42 |
| corneal epithelia | #42 |
| day eye | #42 |
| revised 2010 | #43 |
| limbus corneal | #43 |
| diseases 2017 | #43 |
| keratolimbal | #43 |
| rollable | #43 |
| surface years | #43 |
| instability decreased | #43 |
| meniscus treatment | #43 |
| microscopy central | #43 |
| cytology revealed | #43 |
| hydrocarbons data | #43 |
| eyelid edema | #43 |
| conjunctival hyperemia | #43 |
| activated il4 | #44 |
| il1beta il4 | #44 |
| cautery female | #44 |
| subjective symptom | #44 |
| abovementioned drugs | #44 |
| collagens fibronectin | #44 |
| eye 0001 | #44 |
| agents keratoconjunctivitis | #44 |
| epithelial defect | #44 |
| oct assessment | #44 |
| elasticity patients | #44 |
| tacrolimus treatment | #44 |
| tear meniscus | #44 |
| tryptase par2 | #44 |
| patients rhinoconjunctivitis | #44 |
| topical tacrolimus treatment | #45 |
| formation corneal | #45 |
| superficial punctate keratitis | #45 |
| surgery uncorrected | #45 |
| graded 3 | #45 |
| laser microscopy | #45 |
| metaplasia mucin | #45 |
| case corneal | #45 |
| fibroblasts expression | #45 |
| inflammation ocular surface | #45 |
| body sensation | #45 |
| fibroblasts eosinophils | #45 |
| adult chemotaxis | #45 |
| rose bengal staining | #45 |
| 24 seconds | #45 |
| bovine enteric | #45 |
| micafungin mcfg | #45 |
| signs score | #45 |
| understanding ocular | #45 |
| surface inflammation | #45 |
| fourgrade scale | #45 |
| correlation inflammation | #45 |
| japan particulate | #45 |
| metaplasia grade | #45 |
| recruiting chemokines | #45 |
| users contact | #45 |
| elevation iop | #45 |
| posttreatment findings | #46 |
| tryptases regulation | #46 |
| staining conjunctival | #46 |
| surface disease | #46 |
| seconds controls | #46 |
| suspension effective | #46 |
| corneal cells | #46 |
| 17 japanese patients | #46 |
| graticule | #46 |
| efficacy combined therapy | #46 |
| fluorometholone | #46 |
| conjunctival | #46 |
| status ocular | #46 |
| efficacy 01 | #46 |
| il13 serum | #46 |
| staining inflammatory | #46 |
| visante oct | #47 |
| purpose efficacy | #47 |
| ulcer score | #47 |
| positive muc5ac | #47 |
| allergic female histamine | #47 |
| suspension 4 | #47 |
| diameter plant | #47 |
| blood level | #47 |
| rate ocular | #47 |
| patients 01 | #47 |
| muc5ac mrna | #48 |
| stromal nerve | #48 |
| implantation acrysof | #48 |
| brush cytology specimens | #48 |
| eyelid warming | #48 |
| eyes month | #48 |
| sac patients | #48 |
| stimulation chemokine | #48 |
| complications corneal | #48 |
| enhanced benefits | #48 |
| dexamethasone anti | #48 |
| cyclosporine ophthalmic | #48 |
| trabeculectomy eyes | #49 |
| expression crth2 | #49 |
| eosinophils epithelium | #49 |
| ocular signs | #49 |
| tacrolimus female | #49 |
| 1cu | #49 |
| keratocytes fibroblasts | #49 |
| fibroblasts incubated | #49 |
| adult ca125 | #49 |
| male tears | #49 |
| objective findings | #49 |
| visits air | #49 |
| concentrations tears | #49 |
| cxc chemokine genes | #49 |
| test ocular | #50 |
| measuring corneal | #50 |
| dyes fluorophotometry | #50 |
| ulcers purpose | #50 |
| patient eyes | #50 |
| aged blinking | #50 |
| 4 normal controls | #50 |
| inflammation conjunctiva | #50 |
| schirmers test | #50 |
| meniscus height | #50 |
| decreased tear | #50 |
| disposable soft | #50 |
| total severity score | #50 |
| trabeculectomy mitomycin | #50 |
| ocular surface cells | #51 |
| reduction score | #51 |
| cells brush | #51 |
| scls | #51 |
| diagnosis dry | #51 |
| lenses scls | #51 |
| members japan | #51 |
| inflammation cataract | #51 |
| periostin patients | #51 |
| effects docosahexaenoic acid | #51 |
| crth2 expression | #51 |
| markers atopic | #51 |
| stability corneal | #52 |
| pcr tgf | #52 |
| atopic groups | #52 |
| tears tomography | #52 |
| severity objective | #52 |
| reaction vehicle | #52 |
| eye normal | #52 |
| inflammation decline | #52 |
| biomarker diseases | #52 |
| month initiation | #52 |
| examination parameters | #52 |
| eyelid margins | #52 |
| differential eosinophil | #53 |
| bromfenac | #53 |
| acuity values | #53 |
| stromal nerves | #53 |
| vegf protein secretion | #54 |
| chloride bak | #54 |
| limbic keratoconjunctivitis | #54 |
| presence rsv | #54 |
| lacrimal glands | #54 |
| 005 month | #54 |
| oxidation adolescent | #54 |
| scores tear | #54 |
| obstructive mgd | #54 |
| suspension treatment | #54 |
| combinedtreatment | #55 |
| epithelial cells expression | #55 |
| surface clinical | #55 |
| adult conjunctivitis | #55 |
| atopic enterotoxins | #55 |
| local cytokine production | #55 |
| conjunctiva drug | #55 |
| aged pollen | #55 |
| antagonists allergic | #55 |
| ocular signs symptoms | #55 |
| specular microscopic | #56 |
| pain photophobia | #56 |
| film ocular | #56 |
| dysfunction atopic | #56 |
| mucin2 mucin4 | #56 |
| topical adolescent | #56 |
| plant pollens | #56 |
| allergies adolescent | #56 |
| ded adult | #56 |
| cornea cyclooxygenase | #56 |
| eosinophil cationic | #56 |
| solution placebo | #56 |
| mechanism giant | #56 |
| mucin layer | #56 |
| atopic patients | #56 |
| 3 dry | #56 |
| penetrating limbus | #57 |
| chemotactic responses | #57 |
| accommodating iol | #57 |
| giant papillary conjunctivitis | #57 |
| insensible administration | #57 |
| humans interleukin4 | #57 |
| inflammation pge2 | #57 |
| seventyeight eyes | #58 |
| maximum blood concentration | #58 |
| objective sign | #58 |
| alpha defensins | #58 |
| papilla formation | #58 |
| staining tear | #58 |
| drop treatment | #58 |
| schiff staining | #58 |
| type allergic | #59 |
| pm25 prevalence | #59 |
| tear instability | #59 |
| disease eyes | #59 |
| findings criteria | #59 |
| intraoperative mitomycin | #59 |
| syndromes female | #60 |
| tacrolimus ointment treatment | #60 |
| release inhibitor | #60 |
| diabetic corneal | #60 |
| mmc 2 | #60 |
| daily disposable | #60 |
| signs severe | #60 |
| pcr severe | #60 |
| evaluation items | #60 |
| compared 0001 | #60 |
| thermography adult | #61 |
| punctal | #61 |
| correlation patients | #61 |
| nonsteroidal blotting | #61 |
| expression eyes | #62 |
| eyes 16 | #62 |
| allergen mediated | #62 |
| specimens histopathologic | #62 |
| eotaxin1 expression | #62 |
| combination epithelium | #62 |
| total clinical | #62 |
| amplitude accommodation | #62 |
| prostaglandin patients | #62 |
| values tended | #62 |
| hypersensitivity japan | #63 |
| conjunctiva patients | #63 |
| corneal stem | #63 |
| sac age | #63 |
| patient corneal | #63 |
| il4 role | #63 |
| oral pilocarpine | #63 |
| corneal erosion | #63 |
| micafungin treatment | #63 |
| chamber body | #63 |
| ulcer endophthalmitis | #63 |
| factor allergic | #64 |
| evaluation corneal | #64 |
| eye adolescent | #64 |
| dexamethasone production | #64 |
| positive mucin | #64 |
| density inflammatory | #64 |
| cornea dry | #64 |
| il4 culture | #64 |
| radioimmunoassay respiratory | #64 |
| mucins rna | #65 |
| viral radioimmunoassay | #65 |
| microscope methods | #65 |
| conclusions corneal | #65 |
| live rsv | #65 |
| tears biomarkers | #65 |
| dust house | #65 |
| diagnosis therapies | #66 |
| treatment immunosuppressive agents | #66 |
| layer speed | #66 |
| surface epithelial | #66 |
| cases atopic | #66 |
| persistent epithelial | #67 |
| 003 treatment | #67 |
| agents keratoplasty | #67 |
| female fluorophotometry | #67 |
| period oral | #67 |
| effects 01 | #67 |
| cyclosporine eye | #67 |
| ointment treatment | #68 |
| eye dry | #68 |
| time vital | #68 |
| housedust | #68 |
| ophthalmic solutions | #69 |
| fibroblasts examined | #69 |
| counter drugs | #69 |
| occlusion 005 | #69 |
| fibroblasts corneal | #69 |
| patients eosinophils | #69 |
| aged tears | #69 |
| glaucoma graft | #69 |
| values rose | #70 |
| crth2 pgd2 | #70 |
| 1436 patients | #70 |
| crth2 receptor | #70 |
| rhinoconjunctivitis allergic | #70 |
| 22 eyes | #70 |
| visit 4 | #70 |
| schirmer test | #70 |
| dust 20 | #71 |
| lenses dry | #71 |
| factors tears | #71 |
| allergic dermatitis | #71 |
| drops treatment | #71 |
| 16 eyes | #72 |
| glaucoma trabeculectomy | #72 |
| bulbar conjunctiva | #72 |
| ige eosinophil | #72 |
| tear production | #72 |
| fml | #73 |
| immunosuppressive treatment patients | #73 |
| pyridines pyrimidinones | #73 |
| punctate keratopathy | #73 |
| fluorophotometry humans | #73 |
| epithelial structure | #73 |
| liquid conjunctiva | #73 |
| surface mucins | #73 |
| pollution prevalence | #73 |
| extraction conjunctiva | #73 |
| antiallergic agent | #73 |
| inflammatory cell numbers | #74 |
| evaluation dry | #74 |
| iol acrysof | #74 |
| mcfg | #74 |
| agents intraocular | #74 |
| tacrolimus patients | #74 |
| eosinophils expressed | #74 |
| pilocarpine prospective | #75 |
| 1 month baseline | #75 |
| improved infrared | #75 |
| healthy individuals patients | #75 |
| cedar pollen | #75 |
| laser flare | #75 |
| completely controlled | #75 |
| dust epidemiologic | #75 |
| agents interleukin4 | #76 |
| ccchemokine | #76 |
| guidelines allergic | #76 |
| interleukin4 rna | #76 |
| slight elongation | #77 |
| surgery technique | #77 |
| cornea module | #77 |
| signs treatment | #77 |
| ophthalmological elasticity | #77 |
| lower tear | #77 |
| capilia | #77 |
| cytokines stimulate | #77 |
| chemical mediator | #77 |
| cytology samples | #77 |
| vegf tgfbeta1 | #77 |
| excision recurrence | #77 |
| studies suspensions | #77 |
| drops 1 | #78 |
| concentration il2 | #78 |
| concomitant tacrolimus | #78 |
| severity ocular | #78 |
| pollen compared | #78 |
| signs observed | #78 |
| japanese guideline | #78 |
| glaucoma penetrating | #79 |
| type allergy | #79 |
| injection reduction | #79 |
| il4 ige | #79 |
| inhibitors leupeptin | #79 |
| allergic environmental | #79 |
| dry eye | #79 |
| effects corneal | #79 |
| ocular pain | #79 |
| extended wear | #79 |
| permeability cornea | #79 |
| medications required | #80 |
| assay epithelial | #80 |
| mgd patients | #80 |
| questionnaires tears | #80 |
| mediated par2 | #80 |
| antigens histamine | #81 |
| decreased dry | #81 |
| vegf concentration | #81 |
| atopic dermatitis study | #82 |
| caused insufficient | #82 |
| acrysof iol | #82 |
| prostaglandin reverse | #82 |
| cytology performed | #82 |
| patients conjunctivitis | #82 |
| patients staphylococcus aureus | #83 |
| dental college | #83 |
| tear lipid | #83 |
| expression corneal | #83 |
| data tacrolimus | #83 |
| complications lenses | #83 |
| cytokines vegf | #84 |
| earlier published data | #84 |
| correlation corneal | #84 |
| epithelium ocular | #84 |
| schirmer | #84 |
| papillae | #84 |
| patients dry | #85 |
| hyperemia induced | #85 |
| scleritis patients | #85 |
| inhibitors tryptases | #85 |
| human reverse | #85 |
| alterations basal | #85 |
| 18 pg | #85 |
| treatment odds ratio | #85 |
| temperature patients | #85 |
| 5 grades | #85 |
| combined penetrating | #85 |
| inflammation eye | #86 |
| discharge evaluated | #86 |
| edema scores | #86 |
| sligkv | #86 |
| patients eyelid | #86 |
| 284 years | #86 |
| acuity accommodation | #86 |
| pharmacologic intervention | #86 |
| daily outpatient | #86 |
| confocal ophthalmic | #87 |
| tacrolimus reduced | #87 |
| detection limit assay | #87 |
| tacrolimus young | #87 |
| post keratoplasty | #88 |
| daily weather conditions | #88 |
| disease conjunctiva | #88 |
| regulation muc5ac | #88 |
| cells keratocytes | #88 |
| sclera surgical | #88 |
| tears | #88 |
| eyes 30 | #89 |
| tryptase inhibitors | #89 |
| tears visual | #89 |
| seasonal perennial | #89 |
| findings severe | #89 |
| assessment dry | #89 |
| months signs | #90 |
| lower corneal | #90 |
| cytocentrifuge preparations | #90 |
| decrease corneal | #90 |
| dressings chronic | #90 |
| glands microscopy | #90 |
| early ocular | #90 |
| tears adult | #90 |
| temperature cornea | #90 |
| lenses extended | #91 |
| film breakup | #91 |
| procedures phacoemulsification | #92 |
| techniques trabeculectomy | #92 |
| laser cell | #92 |
| eye corneal | #92 |
| exposure japan | #92 |
| treatment noninfectious | #93 |
| stromal corneal | #93 |
| drug fibroblasts | #93 |
| patients correlation | #93 |
| preschool conjunctiva | #93 |
| 7 visit | #93 |
| tears administration | #93 |
| 005 complications | #93 |
| conjunctival specimens | #93 |
| regulation muc1 | #93 |
| solutions tears | #93 |
| eye cataract surgery | #93 |
| classification pathogenesis | #94 |
| pollution weather | #94 |
| reaction physical | #94 |
| pgd2 crth2 | #94 |
| case allergic | #94 |
| exposure exhaust | #94 |
| eosinophils patients | #95 |
| induced pgd2 | #95 |
| relevant factor | #95 |
| eye higher | #95 |
| studies tears | #95 |
| twentyeight eyes | #95 |
| 128 eyes | #96 |
| staining fluorescein | #96 |
| higher eyes | #96 |
| protein eosinophilia | #96 |
| score objective | #96 |
| study cyclosporine | #96 |
| treatment ecp | #97 |
| production pge2 | #97 |
| 4 alterations | #97 |
| 1month treatment | #97 |
| cells hel | #97 |
| eyes study | #98 |
| eyes positive | #98 |
| eye tear | #98 |
| meniscus patients | #98 |
| staining schirmer | #98 |
| vdts | #98 |
| surgery 6 months | #99 |
| 005 recurrence | #99 |
| management ocular | #99 |
| japan post | #99 |
| cytology evaluation | #99 |
| solution improved | #99 |
| pseudophakic patients | #99 |
| equivalent 4 | #99 |
| postoperatively statistically | #100 |
| ulcer patient | #100 |
| ointments tacrolimus | #100 |
| local pattern | #100 |
| allergic atopic | #100 |
| corneal abnormalities | #100 |
| terminals contact | #100 |
| cells severity | #100 |
| conjunctiva corneal | #100 |
| confocal scanning | #100 |
| fibroblasts 2 | #101 |
| eyes 10 | #101 |
| pathogenesis atopic | #101 |
| effects tranilast | #102 |
| pathogenesis allergic | #102 |
| disease classified | #102 |
| severe atopic | #102 |
| therapy conjunctival | #102 |
| agents conjunctivitis | #102 |
| keratolimbal allograft | #102 |
| chemotaxis experiments | #103 |
| washing solution | #103 |
| prevalence dry | #103 |
| subjective comfort | #103 |
| mediated protease | #103 |
| patients bf | #104 |
| allergic cytokines | #104 |
| topic premedication | #104 |
| syndrome epstein | #104 |
| events scores | #104 |
| tears young | #104 |
| groups dry | #104 |
| topical cyclosporine | #104 |
| differences ocular | #104 |
| values vital | #104 |
| inflammation diagnosis | #105 |
| role staphylococcal | #105 |
| child conjunctival | #105 |
| wearing contact | #105 |
| baseline initiation | #105 |
| aged amnion | #105 |
| conjunctival impression cytology | #105 |
| 14 eyes | #106 |
| parameters ocular | #106 |
| microscopy evaluation | #106 |
| pressure keratoplasty | #106 |
| conjunctiva cornea | #106 |
| adhesion fibroblasts | #106 |
| eotaxin1 | #107 |
| superficial punctate | #107 |
| corneal keratocytes | #107 |
| patients ded | #107 |
| acuity acrylic | #108 |
| lipid layer | #108 |
| resins aged | #108 |
| levels radioimmunoassay | #108 |
| topical tacrolimus | #108 |
| dry mouth symptoms | #108 |
| induces chemotaxis | #108 |
| conjunctiva | #108 |
| scores symptoms | #108 |
| film instability | #108 |
| asian dust | #109 |
| effects dha | #109 |
| tear evaporation | #109 |
| 4 dry | #109 |
| level tacrolimus | #109 |
| il4 human | #109 |
| corneal inflammatory | #109 |
| japanese guidelines | #110 |
| eyes 9 | #110 |
| steroids administration | #110 |
| lacrimal salivary | #110 |
| conjunctival epithelium | #110 |
| increased evaporation | #110 |
| controls inflammatory | #110 |
| dysfunction mgd | #110 |
| topical instillation | #111 |
| severity markers | #111 |
| vcam1 antibody | #112 |
| eye camera | #112 |
| strabismus surgery | #113 |
| dibenzoxepins | #113 |
| anterior segment inflammation | #113 |
| pcr rsv | #113 |
| papillary conjunctivitis | #113 |
| solutions platelet | #113 |
| lesions atopic | #114 |
| layer patients | #114 |
| incision cataract | #114 |
| eye irritation | #114 |
| grading scores | #114 |
| diagnosed allergic | #114 |
| sjögrens syndrome patients | #115 |
| allergic eye | #115 |
| conjunctival cell | #115 |
| seconds 0001 | #115 |
| cholinergic treatment | #115 |
| findings severity | #115 |
| male mucin | #115 |
| goblet cell density | #115 |
| 13 eyes | #115 |
| selective histamine | #116 |
| edition revised | #116 |
| ophthalmology prevalence | #117 |
| viscosupplements aged | #117 |
| asia dust | #117 |
| samples stained | #117 |
| patients seasonal | #117 |
| cooling increased | #117 |
| metaplasia mucins | #117 |
| molecule1 interleukin4 | #118 |
| effects docosahexaenoic | #118 |
| sag genes | #118 |
| generation pge2 | #118 |
| immunologic receptors prostaglandin | #118 |
| topical steroids | #119 |
| chemotaxis induced | #119 |
| revealed higher | #119 |
| skin elasticity | #119 |
| week 005 | #119 |
| acuity distance | #119 |
| iop observed | #119 |
| 39 mmhg | #119 |
| matter prevalence | #120 |
| syndromes epithelium | #120 |
| levels histamine | #121 |
| soft lenses | #121 |
| mitomycin ophthalmic | #121 |
| distance corrected | #121 |
| mitomycinc mmc | #121 |
| chronic allergic | #122 |
| titers ebv | #123 |
| adult conjunctiva | #123 |
| male ointments | #123 |
| artificial tear | #123 |
| collagen conjunctiva | #123 |
| area corneal | #124 |
| eosinophils cell | #124 |
| conjunctival tissues | #125 |
| activity corneal | #125 |
| month reduced | #126 |
| proteaseactivated receptor2 | #126 |
| damage severe | #126 |
| subjects vivo | #127 |
| nerves studied | #127 |
| patients atopic | #127 |
| 05ng | #127 |
| gamma increase | #128 |
| 9 genes | #128 |
| soft contact lenses | #128 |
| elisa levels | #129 |
| 361 ± | #129 |
| fibroblast viability | #129 |
| acds | #129 |
| combination steroids | #129 |
| functional visual | #130 |
| patients insignificant | #130 |
| fva | #130 |
| disease cornea | #131 |
| antigen hladr | #131 |
| eyes fluorescein | #132 |
| management allergic | #132 |
| resection severe | #132 |
| cataract phacoemulsification | #132 |
| eye drop | #132 |
| 5ac | #132 |
| keratoplasty adult | #133 |
| 19 normal subjects | #133 |
| proteins mucin | #133 |
| gene transcription levels | #133 |
| treated tacrolimus | #133 |
| skin water | #133 |
| surface examination | #134 |
| pcr hla | #134 |
| density negative | #134 |
| normal conjunctival | #134 |
| acrylic iol | #134 |
| solutions phacoemulsification | #135 |
| specimens vivo | #135 |
| stress status | #136 |
| iop treatment | #136 |
| eosinophil adhesion | #137 |
| dry eye patients | #137 |
| severity 10 | #137 |
| ocular surface | #137 |
| ophthalmological dry | #137 |
| antiallergic properties | #137 |
| asian dust storms | #138 |
| iol groups | #138 |
| eosinophil cationic protein | #138 |
| allergic dogs | #139 |
| protein ecp | #139 |
| authors technique | #139 |
| ratio remission | #139 |
| suppressed pretreatment | #140 |
| aminobenzoates anti | #141 |
| allergic patients | #141 |
| inflammation prostaglandin | #141 |
| improvements symptom | #142 |
| findings upper | #142 |
| interleukin1 interleukin13 | #142 |
| combination rapid | #143 |
| olopatadine hydrochloride | #143 |
| determine central | #144 |
| cornea cyclosporine | #144 |
| studies scleritis | #144 |
| 52 mmhg | #144 |
| eye syndromes | #145 |
| symptoms ocular | #145 |
| recordable | #145 |
| specimens patient | #145 |
| reticular basement membrane | #146 |
| findings adolescent | #146 |
| schiff reaction | #146 |
| underwent evaluation | #146 |
| virus pathogen | #146 |
| eye clinical | #146 |
| fibroblasts alpha | #146 |
| human conjunctiva | #146 |
| impression cytology | #147 |
| diagnosis atopic | #147 |
| required type | #147 |
| 263 years | #147 |
| dscg | #147 |
| hne 4 | #147 |
| dynamic visual acuity | #148 |
| increased goblet | #148 |
| 0001 corneal | #148 |
| ulcer drug | #148 |
| quantitative evaluation | #149 |
| suspension based | #149 |
| patients allergic | #149 |
| japan phenotype | #149 |
| intraocular lens iol | #149 |
| cationic protein | #149 |
| fibroblasts production | #149 |
| concentration tacrolimus | #149 |
| inflammatory cells | #150 |
| pyrimidinones treatment | #150 |
| japanese cedar pollen | #150 |
| controls performed | #151 |
| inflammation reduction | #151 |
| tacrolimus treated | #152 |
| postoperative secondary | #152 |
| par2 reverse | #152 |
| induced eotaxin | #153 |
| increased fibroblasts | #153 |
| artificial tears | #153 |
| eyes 11 | #153 |
| symptoms objective | #153 |
| 28 surgery | #153 |
| concentrations il4 | #154 |
| grade effects | #155 |
| male mitomycin | #155 |
| inflammation ocular | #155 |
| alcon | #156 |
| association pm25 | #156 |
| chemokine expression | #156 |
| eyelids female | #156 |
| inflammatory ocular | #157 |
| values improved | #157 |
| greater inflammation | #157 |
| pcr increase | #157 |
| analysis prostaglandin | #157 |
| ointments skin | #157 |
| lipid infiltration | #157 |
| rates untreated | #157 |
| japan included | #158 |
| surface status | #158 |
| acuities | #158 |
| trial tacrolimus | #158 |
| weeks adverse | #159 |
| immunological characteristics | #159 |
| 3 boys | #159 |
| study inflammation | #160 |
| chemokines production | #161 |
| mucin 5ac | #161 |
| 28 female | #161 |
| muc16 | #161 |
| thirtysix eyes | #161 |
| elevation study | #161 |
| acid schiff | #161 |
| distance visual acuity | #162 |
| 326 years | #162 |
| male meibomian | #162 |
| surgery topical | #162 |
| bromobenzenes | #162 |
| efficacy tacrolimus | #163 |
| oxidative stress status | #163 |
| visit 7 | #163 |
| olopatadine | #163 |
| il1beta il2 | #163 |
| prevalence ocular | #163 |
| studied 21 | #163 |
| twentynine eyes | #163 |
| 002 treatment | #164 |
| soft contact | #164 |
| spt positive | #164 |
| 30ng | #164 |
| patients topical | #164 |
| steroid anti | #164 |
| purpose reported | #164 |
| production prostaglandin | #165 |
| biological dressings | #165 |
| fluorescein humans | #166 |
| pgd2 induced | #166 |
| cytometry hla | #166 |
| tacrolimus ointment | #167 |
| cytokines allergic | #167 |
| eosinophils higher | #167 |
| ulcers erosions | #168 |
| males 5 | #168 |
| treating refractory | #169 |
| studies tacrolimus | #169 |
| seldi | #169 |
| local allergic | #169 |
| steroidal blotting | #169 |
| 12 males | #169 |
| eotaxin chemokine | #169 |
| patients postsurgical | #169 |
| expression chemokines | #170 |
| status inflammation | #171 |
| management enzyme | #171 |
| conjunctiva conjunctival | #171 |
| subbasal nerve | #172 |
| fibroblasts fibroblast | #173 |
| palisades | #173 |
| distance acuity | #174 |
| slit lamp | #174 |
| subjective symptoms | #174 |
| vivo confocal | #174 |
| pcr flow | #174 |
| status oxidative | #174 |
| standard conventional | #174 |
| 34 eyes | #175 |
| postkeratoplasty | #175 |
| evaluated symptoms | #176 |
| homologous molecule | #176 |
| treatment corneal | #177 |
| dust extract | #177 |
| aldehydes biomarkers | #177 |
| study longterm outcomes | #177 |
| subbasal | #177 |
| strabismus adolescent | #178 |
| acrysof | #178 |
| reduction intraocular pressure | #178 |
| mild 2 | #178 |
| tryptase | #178 |
| endophthalmitis female | #178 |
| chemokine genes | #179 |
| risk ocular | #179 |
| dyes follow | #180 |
| myopic regression | #180 |
| ceramides child | #180 |
| japan young adult | #180 |
| compared eye | #180 |
| 4 female | #180 |
| migration eosinophils | #180 |
| cutometer | #181 |
| lipid study | #181 |
| normal control patients | #181 |
| serum il4 | #183 |
| lipoproteins micafungin | #183 |
| blepharitis | #183 |
| male radioallergosorbent | #184 |
| mucin4 mucins | #185 |
| igg virus | #185 |
| human lymphocyte antigen | #185 |
| nerve prospective | #186 |
| therapy corneal | #186 |
| examined parameters | #186 |
| efficacy topical | #187 |
| par2 mrna | #187 |
| corneal fibroblasts | #187 |
| atopic eosinophils | #187 |
| drug fibroblasts humans | #187 |
| suspensions administration | #187 |
| corneal sensitivity | #188 |
| eye symptoms | #188 |
| 19 eyes | #188 |
| il13 increased | #188 |
| seconds patients | #189 |
| production stromal | #189 |
| sensitivity regulation | #189 |
| allergic cross | #189 |
| levels 33 | #190 |
| assisted infrared | #191 |
| effects diesel | #191 |
| infiltrating eosinophils | #191 |
| tear break | #191 |
| improvement subjective | #192 |
| controls vivo | #193 |
| allergic rhinoconjunctivitis | #193 |
| therapeutic study | #193 |
| 26 eyes | #194 |
| reactivation epstein | #195 |
| expression rantes | #195 |
| fibroblasts inhibited | #195 |
| rigid gas | #196 |
| female histamine | #196 |
| 80 allergens | #197 |
| eyes 21 | #197 |
| tear film stability | #197 |
| treatment topical | #197 |
| interleukin4 production | #197 |
| methods primary | #197 |
| combination topical | #198 |
| 28 eyes | #198 |
| tears time | #198 |
| elisa performed | #198 |
| pollen prospective | #199 |
| effects topical | #199 |
| photorefractive keratectomy | #201 |
| mcp1 ip10 | #201 |
| perennial allergic | #201 |
| preservative free | #201 |
| pollen allergic | #201 |
| hypersensitivity interleukin13 | #202 |
| unit density | #202 |
| rsv infected | #202 |
| receptor homologous | #202 |
| eosinophils neutrophils | #203 |
| ova alum | #204 |
| vcam1 icam1 | #204 |
| pge2 human | #204 |
| differences iop | #204 |
| grade scale | #204 |
| eyes 005 | #205 |
| inflammatory allergic | #205 |
| disease dry | #206 |
| time tbut | #206 |
| eyes cataract | #206 |
| minutes 8 | #206 |
| disease acd | #206 |
| ecp levels | #207 |
| pressure lens | #207 |
| crth2 | #207 |
| formation giant | #207 |
| count cornea | #207 |
| glands middle | #207 |
| size contact | #208 |
| mammalian milk | #208 |
| tears aged | #208 |
| fluorescein fluorescent | #208 |
| analysis pm25 | #209 |
| uncorrected corrected | #209 |
| treatment allergic | #210 |
| human allergic | #210 |
| month reduction | #210 |
| refractory conventional | #211 |
| oct diagnosis | #211 |
| antiallergic drug | #211 |
| combination tests | #212 |
| inflammation injection | #212 |
| iol patients | #212 |
| tacrolimus combination | #212 |
| conjunctiva eye | #213 |
| chamber anti | #213 |
| treated refractory | #213 |
| steroids treatment | #214 |
| muc5ac | #214 |
| alpha il4 | #215 |
| ige higher | #216 |
| allergic agents | #217 |
| conjunctival goblet | #217 |
| worse eyes | #218 |
| lens purpose | #218 |
| expressions higher | #219 |
| nuclear cataract | #219 |
| august october | #220 |
| tranilast | #220 |
| metabolism lysine | #220 |
| conjunctival biopsy | #220 |
| conjunctivitis acute | #221 |
| findings inflammation | #221 |
| cells crth2 | #222 |
| twentyfour eyes | #222 |
| level ambient | #222 |
| samples correlated | #222 |
| diseases dry | #222 |
| combined therapy | #222 |
| 26 control subjects | #224 |
| symptoms short | #224 |
| iop corneal | #224 |
| sensitivity measurements | #224 |
| allergic drug | #225 |
| patients eye | #226 |
| 17 eyes | #227 |
| corneal clarity | #228 |
| eyes adult | #228 |
| treatment 3 months | #228 |
| followup cases | #229 |
| itching | #229 |
| corrected distance | #230 |
| treatment superior | #230 |
| eye signs | #230 |
| exhaust particles | #231 |
| 30 eyes | #231 |
| activity eosinophils | #231 |
| examined level | #232 |
| events initiation | #232 |
| alpha defensin | #232 |
| scleral flap | #232 |
| cyclosporine treatment | #233 |
| concomitantly administered | #233 |
| proteinchip | #233 |
| 791 patients | #233 |
| anti allergic | #233 |
| dye staining | #233 |
| 644 years | #234 |
| examined production | #235 |
| cultured eosinophils | #235 |
| quantitatively evaluate | #236 |
| corneal disease | #236 |
| specimens patients | #236 |
| gamma transcripts | #237 |
| term topical | #237 |
| topical steroid | #238 |
| proliferative lesions | #240 |
| studied subjects | #240 |
| diagnostic abilities | #240 |
| tool quantitative | #240 |
| eyes ocular | #241 |
| bf patients | #241 |
| cell chemotactic | #242 |
| surface lipid | #242 |
| cromolyn sodium | #242 |
| common ocular | #245 |
| performed higher | #245 |
| specular microscopy | #246 |
| subjects males | #247 |
| equivalent 2 | #247 |
| eye drops | #247 |
| specificity cutoff | #248 |
| chemosis | #248 |
| failure visual | #250 |
| labeling intercellular | #251 |
| response prostaglandin | #251 |
| males 13 | #252 |
| syndrome tears | #252 |
| leukocyte child | #252 |
| seasonal allergic | #252 |
| subjective objective | #252 |
| levels tacrolimus | #253 |
| topical oral | #253 |
| improved vision | #255 |
| corneal female | #255 |
| muc | #255 |
| dexamethasone inhibition | #256 |
| stability positive | #256 |
| rantes expression | #256 |
| disease corneal | #257 |
| treating severe | #257 |
| eosinophil chemotaxis | #258 |
| tear | #259 |
| questionnaire objective | #259 |
| eyes control | #260 |
| eosinophil infiltration | #260 |
| month treatment | #260 |
| additional medications | #260 |
| role histamine | #260 |
| human transcription | #261 |
| expression rsv | #261 |
| h1 antagonist | #262 |
| smaller normal | #262 |
| severity adverse | #264 |
| 1 month treatment | #264 |
| aged mucin | #264 |
| immunohistochemistry increased | #264 |
| steroid induced | #265 |
| keratoplasty pkp | #265 |
| eyelid diseases | #266 |
| controls p0001 | #266 |
| data weekly | #267 |
| signs blood | #267 |
| patients sjögren syndrome | #268 |
| respiratory syncytial virus | #268 |
| microscopy negative | #268 |
| treatment atopic | #268 |
| studied production | #268 |
| sodium drug | #269 |
| aged aldehyde | #270 |
| h1 histamine | #270 |
| computer terminals | #270 |
| dry eye symptoms | #271 |
| prevalence allergic | #272 |
| improved visual acuity | #273 |
| aldose reductase inhibitor | #273 |
| 13 males | #273 |
| epithelium endothelium | #274 |
| concentration quantitative | #274 |
| studies stevens | #274 |
| combination eosinophils | #274 |
| meibomian gland dysfunction | #275 |
| patients sjögren | #277 |
| meibomian gland | #277 |
| tear breakup time | #277 |
| individuals pcr | #278 |
| tbut | #278 |
| grading score | #278 |
| 13 females | #279 |
| 0001 diagnosis | #279 |
| bloodaqueous barrier | #279 |
| eyes 14 | #279 |
| interleukin il4 | #280 |
| multifunctional glycoprotein | #280 |
| 10 seconds | #281 |
| required provide | #281 |
| cautery | #282 |
| disease purpose | #282 |
| expressed th2 | #282 |
| gland dysfunction | #284 |
| ige positive | #284 |
| contralateral eye | #285 |
| amniotic membrane | #285 |
| atopic | #286 |
| seasons adolescent | #286 |
| th2 cytokines | #287 |
| cases refractory | #288 |
| layer adult | #288 |
| adult alkylating | #289 |
| study tacrolimus | #289 |
| eyedrops | #291 |
| entericcoated | #291 |
| water child | #292 |
| iop glaucoma | #293 |
| treatment 01 | #294 |
| exponential equation | #294 |
| new antifungal | #294 |
| levels ige | #295 |
| serum periostin | #295 |
| single therapy | #295 |
| surgery statistically | #297 |
| hyperemia | #297 |
| seventy eyes | #299 |
| rose bengal | #300 |
| severity diagnosis | #300 |
| ccl11 chemokine | #300 |
| pkp | #301 |
| benzalkonium chloride | #301 |
| morphologic alterations | #302 |
| assessed based | #303 |
| cobblestone | #303 |
| moderate 3 | #303 |
| photophobia | #304 |
| scanning laser | #304 |
| initiation treatment | #305 |
| operation patient | #305 |
| scores worse | #305 |
| eczema severity | #306 |
| piperidines treatment | #306 |
| assessed 4 | #307 |
| membrane patch | #307 |
| gel application | #308 |
| interleukin13 interleukin2 | #309 |
| evaluation groups | #309 |
| 10 normal subjects | #309 |
| compared simple | #310 |
| inflammatory cell | #310 |
| comfort level | #310 |
| treatment seasonal | #311 |
| cytology specimens | #311 |
| regard age | #311 |
| slitlamp examination | #311 |
| 12 eyes | #311 |
| 7 eyes | #312 |
| molecules chronic | #313 |
| eye adult | #315 |
| aged staining | #315 |
| child corneal | #316 |
| 19 normal | #316 |
| interferometry light | #317 |
| cells cornea | #317 |
| analysis glaucoma | #318 |
| values lower | #319 |
| fluorophotometry | #320 |
| prospective singlearm study | #320 |
| dermatitis clinical | #320 |
| cells chemotaxis | #321 |
| il8 rantes | #321 |
| ulcers | #323 |
| bilateral cataracts | #323 |
| pollen allergen | #324 |
| agreement weighted | #324 |
| 15 30 minutes | #325 |
| eyes 19 | #325 |
| icam1 vcam1 expression | #326 |
| 095 ± | #326 |
| chemokine concentrations | #327 |
| surgery diabetic | #327 |
| transplantation corneal | #328 |
| icam1 antibody | #329 |
| expression goblet | #329 |
| insensible | #330 |
| treatment 2 weeks | #331 |
| pressure ocular | #331 |
| dry eye disease | #332 |
| receptors il2r | #332 |
| leukocyte coculture | #333 |
| values daily | #335 |
| cornea diagnostic | #335 |
| eye treated | #335 |
| proprietary | #336 |
| corneal epithelial | #337 |
| male staphylococcal | #337 |
| 27 eyes | #337 |
| daily wear | #339 |
| signs clinical | #339 |
| eyes 27 | #341 |
| levels epithelial | #341 |
| methods eyes | #342 |
| asthenopia | #343 |
| illness tacrolimus | #344 |
| limbus | #346 |
| corneal infection | #347 |
| measurements treatment | #347 |
| eyes 13 | #348 |
| induced elevation | #348 |
| expression eosinophils | #348 |
| surgery eye | #350 |
| test values | #350 |
| surface diseases | #352 |
| contrast visual | #352 |
| iop elevation | #353 |
| weekly average | #354 |
| expression allergic | #354 |
| temperature infrared | #355 |
| incidence allergic | #355 |
| examination serum | #356 |
| choroidal detachment | #356 |
| patients allergy | #357 |
| tear film | #357 |
| eyes 8 | #358 |
| local cytokine | #358 |
| months conventional | #359 |
| tacrolimus tumor | #359 |
| subjects 13 | #361 |
| difference efficacy | #361 |
| agents benzophenones | #362 |
| aureus patients | #363 |
| messenger blotting | #363 |
| injections lidocaine | #364 |
| function laser | #368 |
| studies sclera | #368 |
| treatment ocular | #368 |
| plant pollen | #368 |
| corneae male | #369 |
| mucin1 mucin2 | #370 |
| postoperative adhesion | #370 |
| eyes 17 | #370 |
| systemic control | #371 |
| cryptomeria japonica | #372 |
| inhibitors epithelium | #372 |
| sixteen eyes | #373 |
| micafungin middle | #374 |
| periodic acid schiff | #374 |
| cornea female | #375 |
| assessment severe | #375 |
| improvement local | #375 |
| retina tomograph | #376 |
| extraction cell | #376 |
| higher human | #377 |
| levels atopic | #377 |
| 4 lower | #377 |
| 10 normal | #377 |
| phacoemulsification prospective | #377 |
| treatment eyes | #378 |
| tarsal | #378 |
| count child | #378 |
| mitomycin | #380 |
| stimulation tnf | #380 |
| cornea eye | #381 |
| corneal inflammation | #381 |
| negative serum | #382 |
| pollinosis | #383 |
| inflammation epithelial | #383 |
| examinations including | #384 |
| gas permeable | #384 |
| vivo corneal | #385 |
| corneal epithelial cells | #386 |
| ocular diseases | #386 |
| limit assay | #388 |
| decrease inflammatory | #388 |
| surgery 13 | #388 |
| surface alterations | #388 |
| healing adult | #389 |
| cells vehicle | #389 |
| sde | #390 |
| severity incidence | #390 |
| antiallergic | #391 |
| patients proteins | #391 |
| breakup time | #393 |
| immunohistochemistry tests | #394 |
| chronic ocular | #395 |
| 44 eyes | #395 |
| applied 5 | #395 |
| relative percentages | #396 |
| opacity corneal | #396 |
| techniques interleukin4 | #396 |
| expression lower | #397 |
| apparatus lacrimal | #397 |
| increased understanding | #398 |
| ocular surface disease | #399 |
| pressure elevation | #399 |
| remission based | #400 |
| declaration helsinki | #400 |
| modified boyden | #401 |
| eyes severe | #401 |
| rays male | #402 |
| sedating humans | #403 |
| cells allergic | #404 |
| weather air | #404 |
| measurements oct | #404 |
| vogt | #404 |
| prospective controlled study | #405 |
| patients epithelial | #406 |
| reproducibility surface | #406 |
| improved diagnosis | #407 |
| serum total ige | #407 |
| 137 years | #407 |
| postoperative aged | #408 |
| activated fibroblasts | #409 |
| heidelberg retina tomograph | #410 |
| confocal | #412 |
| specific total | #412 |
| eyes 15 | #412 |
| acids fibroblasts | #412 |
| 3 months treatment | #413 |
| counts 1 | #413 |
| allergic reaction | #413 |
| keratocytes | #414 |
| postoperative inflammation | #416 |
| limbal | #416 |
| central cornea | #418 |
| penetrating keratoplasty | #418 |
| patients comfort | #419 |
| chemokine ccl11 | #419 |
| speed resolution | #419 |
| mucin4 | #419 |
| sjögren syndrome | #420 |
| ophthalmologist | #420 |
| lacrimal gland | #422 |
| 20 normal controls | #424 |
| 40 minutes | #425 |
| clinical observation | #425 |
| production 4 | #430 |
| trabeculectomy visual | #430 |
| rhinoconjunctivitis | #431 |
| staining score | #431 |
| 0 normal | #433 |
| subjects atopic | #434 |
| cedrus | #437 |
| performed immunohistochemistry | #437 |
| regulation eye | #438 |
| 5 women | #438 |
| methods eye | #438 |
| commercial tests | #439 |
| foldable | #440 |
| subjects studied | #440 |
| interleukin4 il4 | #440 |
| fluorescein dye | #441 |
| regulation chemokine | #441 |
| landolt | #441 |
| vmr | #441 |
| females normal | #442 |
| anti vcam1 | #442 |
| adult aldehydes | #442 |
| male mucin1 | #444 |
| 17 males | #444 |
| patients combined therapy | #445 |
| 39 consecutive patients | #447 |
| dogs dust | #448 |
| air pollution data | #448 |
| male 4 | #450 |
| 30 serum | #450 |
| eye eyes | #451 |
| wash | #452 |
| keratoplasty | #452 |
| versus vehicle | #453 |
| ketotifen | #453 |
| antagonists sedating | #453 |
| normal patients | #454 |
| surface disorder | #454 |
| response allergens | #454 |
| vivo confocal microscopy | #454 |
| water evaporation | #455 |
| production clearance | #455 |
| 8 genes | #455 |
| ophthalmic nerve | #455 |
| agonists pilocarpine | #456 |
| humans keratoplasty | #456 |
| amnion cell | #457 |
| ocular risk | #457 |
| outpatient visits | #457 |
| normal controls patients | #457 |
| checker | #459 |
| oct study | #460 |
| greatest improvements | #461 |
| distance visual | #461 |
| test evaluation | #462 |
| keratoplasty penetrating | #462 |
| hel | #466 |
| unpaired ttest | #467 |
| fibroblasts tgf | #467 |
| study pcr | #468 |
| background atopic | #469 |
| examination diagnosis | #469 |
| major sources | #470 |
| markers severity | #473 |
| allergy adult | #473 |
| metry | #475 |
| diagnosis rate | #476 |
| hladr expression | #476 |
| 13 mmhg | #478 |
| fibroblasts primary | #478 |
| pollen seasons | #478 |
| reduce clinical | #480 |
| height measurement | #480 |
| newly formed vessels | #480 |
| subjects eyes | #481 |
| examined prospective | #482 |
| interleukin 13 | #482 |
| crystalline lens implantation | #485 |
| accommodating | #488 |
| 21 eyes | #488 |
| induced 15 | #489 |
| myopia photorefractive | #490 |
| shortterm study | #490 |
| disodium cromoglycate | #493 |
| prolonged inflammation | #495 |
| ebv reactivation | #495 |
| acuity intraocular | #495 |
| corneal | #498 |
| months eyes | #498 |
| il2 tumor | #499 |
| stain positive | #499 |
| exposure diesel | #499 |
| silicone hydrogel | #500 |
| lens iol | #500 |
| symptoms efficacy | #501 |
| infections viral | #501 |
| treatment eye | #502 |
| pge2 cox2 | #502 |
| studies status | #502 |
| heidelberg retina | #503 |
| 42 eyes | #504 |
| 2 daily | #505 |
| eye position | #505 |
| airborne particulate matter | #506 |
| inflammatory status | #506 |
| correlate severity | #506 |
| penetrating male | #507 |
| induced ocular | #509 |
| aldose reductase | #509 |
| 1 mild | #511 |
| cats child | #512 |
| treatment visual | #514 |
| 45 subjects | #516 |
| topical | #516 |
| disposable equipment | #517 |
| male water | #519 |
| inhibition production | #519 |
| observed baseline | #519 |
| lipopeptides lipoproteins | #520 |
| groups duration | #520 |
| chemoattractant receptor | #522 |
| 01 | #522 |
| metaregression analysis | #523 |
| 10 normal volunteers | #524 |
| infection rsv | #524 |
| studies trabeculectomy | #525 |
| dinoprostone epithelial | #525 |
| trabeculectomy | #527 |
| studies cornea | #527 |
| giemsa staining | #528 |
| density basal | #528 |
| rhodanine | #531 |
| itchy | #531 |
| serum antigen | #535 |
| ocular symptoms | #535 |
| 44yearold | #536 |
| purpose case | #537 |
| patients cataract | #538 |
| total hydrocarbons | #538 |
| dependent migration | #539 |
| sac | #539 |
| capsular bag | #540 |
| placebo tablets | #540 |
| visit 6 | #541 |
| 80 anterior | #541 |
| cases flow | #542 |
| administration topical | #542 |
| infrared radiation | #543 |
| 20 normal | #543 |
| 6 male | #544 |
| production cultured | #546 |
| ebv nuclear antigen | #546 |
| time improved | #547 |
| pollution allergens | #549 |
| periodic acid | #549 |
| film layer | #550 |
| prospective comparative study | #550 |
| il‐4 | #552 |
| cryptomeria | #552 |
| disease complicated | #553 |
| effects cooling | #553 |
| engorgement | #554 |
| fibroblasts response | #555 |
| genechip | #555 |
| disease ded | #555 |
| setting department | #556 |
| noninfected cells | #557 |
| transplantation combined | #558 |
| density assessed | #558 |
| diesel exhaust particles | #559 |
| methods thirty | #559 |
| ocular infections | #560 |
| differentiation inflammatory | #560 |
| eyes iop | #560 |
| eyes 24 | #562 |
| laser trabeculoplasty | #562 |
| positive 30 | #563 |
| count corneal | #569 |
| 16 age | #569 |
| levels il4 | #570 |
| cultured corneal | #570 |
| meibomian | #572 |
| female humans specificity | #576 |
| allergen challenge | #577 |
| corneal diseases | #578 |
| iop eyes | #580 |
| 4 mrna | #580 |
| lesions normal | #582 |
| fibrosis fluorescent | #582 |
| apparatus male | #582 |
| tnfalpha stimulation | #584 |
| increase vegf | #584 |
| department ophthalmology | #584 |
| symptoms scores | #588 |
| female humans allergic | #589 |
| hladr antigen | #589 |
| intraocular male | #589 |
| patients csa | #589 |
| corneal epithelium | #589 |
| induced 4 | #589 |
| study lipid | #590 |
| diseases regulation | #591 |
| icam1 vcam1 | #592 |
| cytological techniques | #593 |
| observed real | #595 |
| findings evaluated | #597 |
| assay eye | #597 |
| epithelium corneal | #598 |
| cells chemokine | #599 |
| diesel exhaust | #602 |
| cornea epithelium | #603 |
| mrna tgf | #604 |
| thermometer | #605 |
| grading scale | #606 |
| inflammation status | #609 |
| topical adult | #609 |
| thermography | #611 |
| corneal nerves | #611 |
| eosinophils epithelial | #612 |
| fluorescent dyes humans | #613 |
| synergic | #614 |
| antagonists humans | #615 |
| patients complained | #615 |
| cells oligopeptides | #616 |
| diagnosis type | #616 |
| grades 0 | #617 |
| ocular allergy | #617 |
| flaps suture | #618 |
| subjects conclusion | #621 |
| il4 | #623 |
| years studied | #625 |
| lamp examination | #625 |
| glaucoma medications | #625 |
| ophthalmologists | #626 |
| occlusion treatment | #628 |
| micafungin | #635 |
| burning sensation | #636 |
| corneal haze | #636 |
| redness | #636 |
| patients tacrolimus | #636 |
| total immunoglobulin | #638 |
| contact lenses | #639 |
| based severity | #639 |
| eosinophils | #639 |
| 511 patients | #640 |
| male rhinitis | #640 |
| development allergic | #641 |
| 11 eyes | #641 |
| months 01 | #643 |
| symptoms signs | #643 |
| performed modified | #643 |
| observed follow | #644 |
| mellitus double | #645 |
| fibrosis actins | #645 |
| patients healthy volunteers | #650 |
| 2 females | #651 |
| expression administration | #651 |
| viscosupplements | #651 |
| analysis existence | #654 |
| eosinophils flow | #654 |
| diseases methods | #656 |
| lacrimal | #657 |
| comfortable | #657 |
| patients elisa | #660 |
| nerve density | #661 |
| 96well plate | #661 |
| chamber technique | #662 |
| treatment 0001 | #664 |
| lens wearers | #664 |
| acuity measured | #665 |
| molecule1 cell | #668 |
| 10 age | #669 |
| damage scores | #669 |
| viruses acute | #669 |
| cedar | #672 |
| stimulation rna | #672 |
| 11 males | #673 |
| humans lacrimal | #673 |
| scleritis | #677 |
| levels correlation | #678 |
| administration ophthalmic | #680 |
| test methods | #681 |
| adherence anti | #681 |
| antibody negative | #682 |
| chemokine gene | #683 |
| stainings | #684 |
| fibronectin cell | #684 |
| single visit | #685 |
| goblet | #686 |
| cells collected | #688 |
| differential diagnosis patients | #689 |
| visual acuity patients | #690 |
| cells eye | #694 |
| atopic female humans | #694 |
| 1 test | #695 |
| inhibition expression | #697 |
| early antigen | #697 |
| objective assessments | #700 |
| levels detection | #700 |
| cromolyn | #700 |
| intraocular inflammation | #703 |
| eyelid | #704 |
| labeling surface | #705 |
| antineoplastic child | #707 |
| participants eyes | #709 |
| pain baseline | #711 |
| allergens child | #712 |
| 1 month | #715 |
| fibroblasts flow | #715 |
| major characteristic | #717 |
| key cells | #718 |
| 5 eyes | #718 |
| dibenzazepines | #719 |
| preventing recurrence | #721 |
| production vascular | #722 |
| 088 ± | #724 |
| 32 eyes | #724 |
| promising treatment strategy | #725 |
| squamous metaplasia | #729 |
| 11 male | #730 |
| followup treatment | #730 |
| aged ophthalmology | #730 |
| cytology patients | #731 |
| eyes underwent | #733 |
| pollution data | #735 |
| suppressive effects | #736 |
| symptoms 5 | #737 |
| reductase inhibitor | #737 |
| intraocular lens | #740 |
| keratectomy | #741 |
| density compared | #741 |
| expression real | #744 |
| definition classification | #746 |
| unpaired test | #746 |
| blood eosinophils | #746 |
| inflammation lipid | #748 |
| purpose hypothesis | #749 |
| cornea corneal | #751 |
| daily weather | #751 |
| interleukin13 male | #752 |
| fibroblasts cultured | #754 |
| eyes 6 | #758 |
| iol implantation | #759 |
| follow cases | #759 |
| allergens anti | #762 |
| trabeculectomy treatment | #763 |
| intraocular lens implantation | #763 |
| topical aged | #763 |
| 148 years | #764 |
| drugs primary | #765 |
| aged chemokine | #766 |
| pathogenesis severe | #769 |
| oligopeptides rna | #769 |
| measurements improved | #772 |
| pge2 production | #775 |
| eotaxin | #776 |
| cells adolescent | #782 |
| role allergic | #783 |
| levels prostaglandin | #783 |
| fluorescein fluoresceins | #784 |
| limbus corneae | #784 |
| purpose analyze | #785 |
| treatment 1 | #785 |
| blinking | #785 |
| elevated levels | #789 |
| allergic disease | #790 |
| eyes normal | #792 |
| lenses intraocular | #792 |
| increased epithelial | #793 |
| tacrolimus | #793 |
| techniques laminin | #793 |
| 4 hne | #794 |
| ocular inflammation | #794 |
| months visual | #798 |
| treatment p0001 | #800 |
| report efficacy | #801 |
| positive linear | #801 |
| radioallergosorbent | #802 |
| excimer male | #804 |
| cells western | #806 |
| receptors ccr3 | #813 |
| mucin | #813 |
| 21 individuals | #814 |
| brush | #816 |
| acuity adolescent | #817 |
| biomicroscopy | #819 |
| concentration dose | #820 |
| aged cell | #820 |
| cells eosinophils | #821 |
| interleukin4 | #821 |
| phenotype practice | #822 |
| temperature case | #825 |
| year adolescent | #831 |
| lymphocytes compared | #834 |
| preoperative level | #834 |
| surgical outcome | #835 |
| cases follow | #835 |
| pachymetry | #840 |
| patients operation | #841 |
| individuals patients | #841 |
| implantation intraocular | #842 |
| ocular adolescent | #843 |
| symptoms improved | #843 |
| elevated iop | #845 |
| new surgical technique | #845 |
| 2 weeks treatment | #848 |
| exhaust | #848 |
| levels air | #848 |
| loss insensible | #851 |
| fluorescein | #853 |
| purpose prospectively | #855 |
| cell area | #855 |
| 10 eyes | #858 |
| methane hydrocarbons | #860 |
| inhibitors diclofenac | #861 |
| myopic eyes | #861 |
| thiazolidines | #865 |
| histamine h1 | #865 |
| thirteen cases | #866 |
| patients ocular | #867 |
| test kits | #868 |
| serum antibody titers | #872 |
| patients eyes | #874 |
| 01 compared | #874 |
| dry eyes | #876 |
| mitomycinc | #878 |
| syndrome sjs | #879 |
| evaluation early | #880 |
| h1 antagonists | #880 |
| benzamidine | #880 |
| patient comfort | #881 |
| cells contributes | #882 |
| assessing efficacy | #882 |
| diseases background | #883 |
| study eye | #886 |
| patients condition | #887 |
| bleb | #887 |
| specular | #890 |
| 114 years | #894 |
| respiratory syncytial | #894 |
| age eye | #895 |
| noncomparative | #897 |
| pain inflammation | #901 |
| ocular | #902 |
| levels pm25 | #903 |
| 20 eyes | #904 |
| benzophenones | #905 |
| decreased baseline | #905 |
| circulating autoantibodies | #907 |
| clinical signs | #910 |
| lacrimal duct | #911 |
| examined pcr | #911 |
| aureus young | #912 |
| gauze | #917 |
| corneae | #919 |
| sjögren | #920 |
| immunoglobulin immunosuppressive | #921 |
| 10 females | #925 |
| treatment symptoms | #928 |
| 8 males | #928 |
| epithelial lesions | #929 |
| immunoregulatory effects | #929 |
| histopathologic analysis | #930 |
| disease efficacy | #932 |
| ophthalmologic surgical | #933 |
| normal controls | #933 |
| beta1 tumor | #937 |
| epithelialization | #937 |
| iop measured | #939 |
| treatment severe | #940 |
| symptoms evaluated | #941 |
| cytokines epithelial | #941 |
| normal 1 | #943 |
| factor production | #946 |
| humans muscarinic | #946 |
| wheal | #947 |
| mgd | #949 |
| radioallergosorbent test | #949 |
| seasons young | #950 |
| humans lenses | #950 |
| ulcer humans | #952 |
| sensitivity values | #953 |
| scanning confocal | #957 |
| 2 moderate | #957 |
| 3 eyes | #959 |
| aldose | #959 |
| singleagent therapy | #959 |
| endpoint baseline | #960 |
| intracellular infection | #961 |
| sedating | #961 |
| expression 8 | #962 |
| dust mites | #963 |
| observed 3 | #965 |
| eyes 12 | #966 |
| ecp | #967 |
| total score | #968 |
| expression chemokine | #969 |
| positively stained | #971 |
| basal epithelial | #973 |
| term therapeutic | #973 |
| mcp1 gene | #980 |
| day month | #981 |
| 6 males | #983 |
| detected patients | #985 |
| ointment | #989 |
| 4 regulation | #990 |
| primary cultured | #992 |
| carried patients | #993 |
| observed conclusions | #994 |
| tenon | #994 |
| technique 2 | #998 |
| adult cornea | #1001 |
| methods sixteen | #1002 |
| observed vivo | #1002 |
| serum ige | #1005 |
| pediatric subjects | #1008 |
| accommodation ocular | #1009 |
| boyden | #1011 |
| time year | #1012 |
| eye infections | #1012 |
| piperidines pyridines | #1013 |
| allergic diseases | #1014 |
| 1 2 weeks | #1017 |
| blink | #1017 |
| impression | #1019 |
| normal volunteers | #1019 |
| improved 1 | #1020 |
| cells positively | #1021 |
| ω3 fatty acids | #1024 |
| model allergic | #1028 |
| studied prospectively | #1029 |
| induced chemotaxis | #1031 |
| diopter | #1032 |
| improved 3 | #1033 |
| 2 eyes | #1036 |
| 045 ± | #1040 |
| patching | #1040 |
| webbased questionnaire | #1040 |
| chemotaxis | #1042 |
| values analysis | #1043 |
| cells fibroblasts | #1044 |
| lysine 4 | #1044 |
| treatment skin | #1045 |
| concomitantly | #1045 |
| xerophthalmia | #1046 |
| recurrence 6 | #1050 |
| indirect humans | #1050 |
| allergen extracts | #1053 |
| symptoms score | #1054 |
| johnson syndrome | #1057 |
| eyelids | #1059 |
| study therapeutic | #1060 |
| allograft transplantation | #1062 |
| guidelines clinical | #1064 |
| giemsa | #1065 |
| pollution risk | #1067 |
| staphylococcal enterotoxin | #1067 |
| disposable | #1067 |
| noninfectious | #1070 |
| acuity patients | #1071 |
| goblet cell | #1071 |
| immunocytochemical study | #1073 |
| months corrected | #1075 |
| effective treating | #1075 |
| eyes received | #1076 |
| efficacy treatment | #1077 |
| benzamidines | #1079 |
| syncytial virus | #1080 |
| techniques ophthalmological | #1080 |
| ade | #1080 |
| expression icam1 | #1082 |
| allergic inflammatory | #1082 |
| sex matched | #1088 |
| cyclosporine patients | #1091 |
| ige anti | #1098 |
| corrected visual acuity | #1099 |
| assessed vivo | #1104 |
| diseases objective | #1104 |
| endothelium corneal | #1107 |
| 10 males | #1109 |
| meibomian glands | #1110 |
| rose | #1116 |
| lens capsule | #1116 |
| 30 patients | #1118 |
| drops | #1121 |
| keratopathy | #1121 |
| popularization | #1122 |
| 92 years | #1122 |
| periostin | #1125 |
| epithelium female | #1132 |
| cultures human | #1133 |
| treatment objective | #1133 |
| assay fibroblasts | #1133 |
| clinical findings | #1133 |
| anti icam1 | #1134 |
| evaluate therapeutic | #1136 |
| controls examined | #1137 |
| healthy eyes | #1140 |
| visual acuities | #1140 |
| prospective controlled | #1141 |
| small incision | #1143 |
| p0035 | #1146 |
| 4 daily | #1146 |
| minimum angle | #1149 |
| aphakic | #1150 |
| aged phacoemulsification | #1153 |
| cyclosporine humans | #1154 |
| interventional case | #1157 |
| airborne particulate | #1165 |
| sjögrens syndrome | #1171 |
| purpose evaluate | #1171 |
| glands sjogren | #1173 |
| cornea | #1173 |
| immune mechanisms | #1189 |
| ophthalmological female | #1189 |
| fibronectins fibrosis | #1189 |
| adult dermatitis | #1191 |
| levels chemokines | #1191 |
| spatial temporal resolution | #1193 |
| cytokine mrna | #1195 |
| refractory standard | #1207 |
| ded | #1209 |
| 84 ± | #1210 |
| concentrations alpha | #1210 |
| 18 females | #1211 |
| boyden chamber | #1212 |
| lasers excimer | #1215 |
| bengal | #1217 |
| scl | #1219 |
| stevens johnson | #1220 |
| par2 | #1222 |
| 025 | #1223 |
| mmc | #1230 |
| microscopy confocal | #1231 |
| allergic inflammation | #1233 |
| instilled | #1235 |
| correlation clinical | #1240 |
| wearers | #1241 |
| eyes treated | #1242 |
| muc5ac expression | #1249 |
| supply adult | #1254 |
| molecule expressed | #1265 |
| messenger reverse | #1266 |
| levels pge2 | #1270 |
| tomograph | #1271 |
| 4 normal | #1274 |
| period clinical | #1275 |
| anesthesia local | #1278 |
| study eyes | #1286 |
| aged substance | #1286 |
| 169 ± | #1287 |
| lacrimal apparatus | #1288 |
| dermatitis atopic | #1289 |
| phacoemulsification | #1290 |
| iol | #1294 |
| cac | #1300 |
| adult antibiotics | #1301 |
| controls 005 | #1302 |
| dryness | #1303 |
| photorefractive | #1304 |
| spring autumn | #1307 |
| intraocular lenses | #1308 |
| japanese cedar | #1310 |
| thermometry | #1311 |
| allergic | #1314 |
| chemokines chemotaxis | #1316 |
| higher severe | #1316 |
| corneal humans | #1317 |
| presence increased | #1318 |
| expressed secreted | #1321 |
| child chromatography | #1321 |
| ccl11 | #1322 |
| 830 | #1322 |
| membrane increased | #1331 |
| treatment improvements | #1334 |
| prostaglandin production | #1335 |
| light lipid | #1337 |
| ccr3 receptors | #1340 |
| fivepoint scale | #1341 |
| operation patients | #1343 |
| ped | #1348 |
| treatment 14 | #1353 |
| antigen child | #1360 |
| benzalkonium | #1365 |
| responses peripheral | #1371 |
| cytokines dinoprostone | #1374 |
| atopic diseases | #1377 |
| 00001 lower | #1383 |
| timeseries analysis | #1384 |
| ointments | #1396 |
| female glucocorticoids | #1399 |
| 18 eyes | #1399 |
| respiratory pathogen | #1404 |
| epithelial barrier function | #1407 |
| diseases diagnosis | #1413 |
| proteaseactivated receptor | #1413 |
| adult allergens | #1414 |
| normal adults | #1416 |
| 005 1 | #1419 |
| 1 week | #1425 |
| prospective comparative | #1428 |
| higher contrast | #1431 |
| patients cgvhd | #1432 |
| rast | #1434 |
| factors seasons | #1439 |
| haze | #1444 |
| corneal neovascularization | #1444 |
| temperature cell | #1445 |
| reduced 1 | #1451 |
| goblet cells | #1451 |
| macular oedema | #1453 |
| histocytological | #1458 |
| corneal opacity | #1465 |
| lens implantation | #1469 |
| complained | #1470 |
| production il4 | #1481 |
| outcome administration | #1488 |
| corneal edema | #1489 |
| data daily | #1497 |
| 2 minutes | #1498 |
| western cells | #1499 |
| detected frequently | #1499 |
| male metaplasia | #1500 |
| bulbar | #1502 |
| studies suture | #1502 |
| pgd2 | #1505 |
| human corneal | #1507 |
| ophthalmological | #1510 |
| staining | #1514 |
| female fluorescein | #1514 |
| 40 mmhg | #1522 |
| studies glaucoma | #1524 |
| total scores | #1526 |
| eosinophils female | #1527 |
| acuity adult | #1530 |
| inhibitors child | #1533 |
| cells density | #1537 |
| 7 females | #1541 |
| production primary | #1542 |
| cytometric analysis | #1544 |
| dioxide particulate | #1548 |
| virus rsv | #1553 |
| pollen rhinitis | #1559 |
| decreased treatment | #1560 |
| steroidal cell | #1566 |
| aged allergens | #1571 |
| fibronectin laminin | #1573 |
| cells 001 | #1575 |
| 15 females | #1580 |
| purpose investigate | #1581 |
| fibroblasts | #1583 |
| effective long | #1589 |
| assessed quantitative | #1591 |
| aldehyde reductase | #1597 |
| preservative | #1602 |
| ortho aminobenzoates | #1602 |
| cells 0001 | #1603 |
| humans intraocular | #1624 |
| vdt | #1624 |
| incidence adverse events | #1625 |
| weeks administration | #1629 |
| eye | #1630 |
| cyclosporine female | #1637 |
| epstein‐barr virus | #1638 |
| epsteinbarr virus ebv | #1641 |
| mitomycin mmc | #1643 |
| preschool dermatitis | #1644 |
| capsule crystalline | #1654 |
| subjects examined | #1658 |
| prevalence severe | #1662 |
| 10 healthy controls | #1663 |
| syncytial | #1663 |
| reaction young | #1665 |
| damage patients | #1666 |
| function small | #1670 |
| infections fungal | #1673 |
| higher normal | #1674 |
| 2 cytokine | #1685 |
| pm25 levels | #1686 |
| dose equivalent | #1687 |
| confocal middle | #1698 |
| 7 males | #1711 |
| outcome visual | #1713 |
| disease defined | #1713 |
| subjects adolescent | #1716 |
| whitney test | #1721 |
| 744 | #1725 |
| topical application | #1735 |
| central corneal | #1741 |
| cytology | #1741 |
| treatment short | #1742 |
| years 19 | #1754 |
| severity treatment | #1754 |
| antigen anti | #1756 |
| iols | #1760 |
| rsv infection | #1761 |
| eightysix patients | #1764 |
| oral steroids | #1775 |
| inflammation assessed | #1779 |
| enterotoxins female | #1789 |
| alpha sma | #1798 |
| mild cases | #1802 |
| 10 healthy | #1811 |
| endophthalmitis eye | #1815 |
| punctate | #1817 |
| antifungal treatment | #1821 |
| receptor par2 | #1823 |
| japan methods | #1823 |
| regulated activation | #1825 |
| sjs | #1827 |
| 15 minutes | #1828 |
| eosinophil | #1828 |
| child dermatitis | #1832 |
| mediator release | #1835 |
| epithelial damage | #1835 |
| factor tnfalpha | #1836 |
| fibroblasts normal | #1837 |
| corneal transplantation | #1838 |
| degrees 4 | #1839 |
| eye examination | #1840 |
| prostaglandin receptors | #1841 |
| inflammation injections | #1842 |
| month 3 | #1846 |
| effects aged | #1848 |
| receptors prostaglandin | #1853 |
| ulcer female | #1857 |
| 005 differences | #1858 |
| comparative evaluation | #1860 |
| shield | #1860 |
| ari | #1862 |
| tnfalpha production | #1862 |
| humans immunosuppressive | #1874 |
| surgery purpose | #1890 |
| cataract surgery | #1893 |
| aphakia | #1893 |
| ige production | #1900 |
| cells epithelial | #1909 |
| sterilized | #1912 |
| interleukin 4 | #1920 |
| ihc staining | #1923 |
| mast cell degranulation | #1929 |
| contact female | #1935 |
| contribute pathogenesis | #1942 |
| 013 ± | #1943 |
| severe persistent | #1946 |
| protein female | #1946 |
| patients exhibited | #1947 |
| score clinical | #1961 |
| vcam1 expression | #1962 |
| 9 males | #1970 |
| 5 minutes | #1970 |
| 4 males | #1971 |
| device treatment | #1972 |
| comfort | #1972 |
| gpc | #1974 |
| corrected visual | #1974 |
| month 1 | #1975 |
| intraocular | #1977 |
| nonuse | #1979 |
| eyes | #1980 |
| controls p005 | #1984 |
| females age | #1990 |
| studies cell | #1992 |
| irritation | #1994 |
| bak | #1999 |
| reaction serine | #2013 |
| diseases diagnostic | #2014 |
| erosions | #2016 |
| agents male | #2023 |
| tacrolimus adult | #2023 |
| surgery 1 | #2025 |
| ccl5 chemokines | #2026 |
| chemotaxis leukocyte | #2031 |
| increased vegf | #2036 |
| treated eyes | #2038 |
| coherence treatment | #2038 |
| based incidence | #2048 |
| eye female | #2049 |
| corneal topography | #2066 |
| ambient air pollution | #2067 |
| versus normal | #2067 |
| allergens animals | #2067 |
| pollen | #2068 |
| dexamethasone enzyme | #2073 |
| herpetic | #2075 |
| temperature measured | #2078 |
| cytokines enzyme | #2084 |
| ophthalmologic | #2091 |
| cytokines dose | #2093 |
| therapeutic effects | #2106 |
| aged antifungal | #2107 |
| activation normal | #2108 |
| clinical examinations | #2112 |
| cultured chemokine | #2118 |
| average concentrations | #2119 |
| acd | #2127 |
| reaction statistics | #2128 |
| human α | #2132 |
| docosahexaenoic acid | #2137 |
| endopeptidases serine | #2137 |
| mucin2 | #2140 |
| antibody positive | #2142 |
| vegf production | #2143 |
| incidence adverse | #2148 |
| scored | #2157 |
| controls 0001 | #2158 |
| expression patient | #2160 |
| umin | #2163 |
| curve reproducibility | #2164 |
| production inhibited | #2164 |
| virus human | #2170 |
| study flow | #2171 |
| density lower | #2174 |
| pressure iop | #2177 |
| sensation | #2181 |
| dyes humans | #2183 |
| adult administration | #2184 |
| regulation adolescent | #2185 |
| eyes patients | #2186 |
| eye disease | #2190 |
| child computer | #2191 |
| diseases female | #2192 |
| aged mitomycin | #2192 |
| duct obstruction | #2202 |
| pseudophakic | #2208 |
| ulcer patients | #2219 |
| cases severe | #2231 |
| greater concentrations | #2232 |
| 1 3 months | #2234 |
| immunoglobulin male | #2235 |
| upper lower | #2236 |
| matter pm25 | #2243 |
| vital | #2246 |
| rater agreement | #2246 |
| scores correlated | #2247 |
| pollens | #2247 |
| allergic seasonal | #2250 |
| groups difference | #2250 |
| tryptases | #2264 |
| compared vehicle | #2265 |
| individuals adolescent | #2270 |
| myopic | #2271 |
| slit | #2275 |
| il4 il13 | #2279 |
| exposure particulate | #2280 |
| uncorrected | #2284 |
| studies stem | #2285 |
| 6 months | #2290 |
| diseases enzyme | #2294 |
| cooling | #2297 |
| female gels | #2302 |
| humans hypersensitivity | #2311 |
| topical treatment | #2312 |
| clinical appearance | #2312 |
| rsv | #2316 |
| performed treatment | #2323 |
| animal study | #2332 |
| hours dose | #2336 |
| il4 production | #2339 |
| culture supernatants | #2343 |
| weeks 1 | #2344 |
| mann whitney | #2351 |
| ca125 antigen | #2354 |
| method assessing | #2371 |
| syncytial viruses | #2377 |
| skin adolescent | #2378 |
| treatment 2 | #2392 |
| immunosuppressive agents | #2409 |
| relieving | #2410 |
| months initiation | #2412 |
| aged nitrogen | #2415 |
| ophthalmology | #2415 |
| child enzyme | #2420 |
| stevens | #2422 |
| effective patients | #2424 |
| intraocular pressure | #2425 |
| prostaglandin | #2433 |
| interleukin2 receptors | #2456 |
| transcription levels | #2459 |
| sclera | #2464 |
| glaucoma humans | #2492 |
| ige antibody | #2493 |
| enteric coated | #2498 |
| fungal female | #2498 |
| diseases adolescent | #2503 |
| scores clinical | #2510 |
| obstruction male | #2513 |
| histamine | #2514 |
| h1 receptor | #2516 |
| histamine humans | #2533 |
| humans hyperemia | #2535 |
| levels alpha | #2543 |
| ebv | #2546 |
| patients symptoms | #2550 |
| cell expressed | #2557 |
| correlated severity | #2565 |
| methods clinical | #2571 |
| oct | #2571 |
| flare | #2573 |
| male polymerase | #2573 |
| controls serum | #2578 |
| penetrating | #2579 |
| mannwhitney | #2580 |
| vcam1 | #2583 |
| tonometry ocular | #2587 |
| aged myopia | #2593 |
| excimer laser | #2597 |
| methods subjects | #2602 |
| fibroblasts humans | #2610 |
| subjects 12 | #2614 |
| complications adolescent | #2619 |
| baseline treatment | #2620 |
| contact lens | #2624 |
| postsurgical | #2629 |
| eosinophilia female | #2629 |
| 6 months treatment | #2638 |
| lamp | #2646 |
| cyclosporine drug | #2647 |
| cyclosporine csa | #2653 |
| alpha adolescent | #2655 |
| 412 | #2656 |
| administered day | #2664 |
| rantes | #2665 |
| mucins | #2672 |
| cataract extraction | #2683 |
| symptom score | #2687 |
| infections respiratory | #2694 |
| groups differences | #2695 |
| tearing | #2698 |
| bf | #2698 |
| chemokine ccl5 | #2712 |
| studies glucocorticoids | #2717 |
| control eyes | #2721 |
| muc1 | #2726 |
| fibroblasts gene | #2731 |
| alpha vascular | #2735 |
| chemokine production | #2739 |
| hne | #2743 |
| factors chemotaxis | #2746 |
| laser scanning | #2747 |
| tomography oct | #2754 |
| immunocytochemical staining | #2759 |
| betamethasone | #2761 |
| matched normal | #2772 |
| total ige | #2772 |
| atopic female | #2773 |
| chronic graft | #2786 |
| humans immunoenzyme | #2792 |
| symptomatic improvement | #2794 |
| prevention adolescent | #2797 |
| male adolescent | #2813 |
| iop | #2817 |
| scores lower | #2818 |
| whitney | #2819 |
| atopic dermatitis | #2821 |
| higher cases | #2821 |
| dry | #2840 |
| groups normal | #2842 |
| analog scale | #2845 |
| aminobenzoates | #2846 |
| months surgery | #2850 |
| crystalline lens | #2855 |
| treatment 4 | #2868 |
| fibroblasts fibronectins | #2889 |
| qol scores | #2892 |
| syndrome patients | #2902 |
| evaporation rate | #2903 |
| mannwhitney test | #2905 |
| anterior chamber | #2907 |
| test performed | #2907 |
| il1beta | #2910 |
| tests diagnosis | #2922 |
| postoperative follow | #2926 |
| drop | #2927 |
| cgvhd | #2929 |
| surgery 2 | #2932 |
| eye diseases | #2940 |
| interleukin8 il8 | #2953 |
| endophthalmitis | #2955 |
| refraction ocular | #2961 |
| excision | #2987 |
| inter rater | #3000 |
| measured elisa | #3014 |
| eosinophils humans | #3014 |
| normal eyes | #3037 |
| cultured chemokines | #3051 |
| agents interferon | #3054 |
| protease activated | #3059 |
| staining labeling | #3068 |
| safety assessed | #3072 |
| evaporation | #3080 |
| aged anti | #3083 |
| treatment total | #3085 |
| immunologic receptors | #3118 |
| baseline month | #3124 |
| rtpcr | #3132 |
| expression adhesion | #3132 |
| dermatitis | #3150 |
| vehicle | #3153 |
| cells graft | #3163 |
| susceptibility humans | #3175 |
| symptom scores | #3181 |
| cell count | #3181 |
| methods seventy | #3188 |
| 10 patients | #3190 |
| investigate efficacy | #3197 |
| recruited study | #3208 |
| sjogren syndrome | #3228 |
| study medication | #3240 |
| patient global | #3249 |
| cell densities | #3269 |
| accommodation | #3274 |
| acuity | #3280 |
| meniscus | #3289 |
| variance case | #3295 |
| interferometry | #3299 |
| normal control subjects | #3302 |
| intraoperative male | #3322 |
| allergens | #3325 |
| cells assessed | #3332 |
| subjective | #3340 |
| efficacy anti | #3343 |
| diclofenac sodium | #3345 |
| dressings | #3352 |
| histamine receptor | #3356 |
| cellular level | #3367 |
| pfu | #3369 |
| diabetic patients | #3375 |
| fibroblast proliferation | #3377 |
| coherence tomography | #3398 |
| ova | #3409 |
| instillation | #3411 |
| normal subjects | #3415 |
| air pollutants | #3416 |
| alpha cell | #3440 |
| patients obstructive | #3460 |
| host disease humans | #3469 |
| papilla | #3493 |
| cataract | #3514 |
| local excision | #3555 |
| interleukin8 male | #3570 |
| visual analog | #3572 |
| agents steroidal | #3585 |
| sjogren | #3591 |
| tokyo | #3609 |
| immunoglobulin ige | #3614 |
| signs | #3617 |
| agents incidence | #3623 |
| plaque formation | #3626 |
| weeks surgery | #3640 |
| method enzyme | #3648 |
| pressure male | #3653 |
| cell density | #3654 |
| fiftytwo patients | #3661 |
| adult chronic | #3668 |
| disease adolescent | #3694 |
| vegf mrna | #3694 |
| 016 ± | #3698 |
| cytological | #3709 |
| 29 years | #3711 |
| gels humans | #3720 |
| week 1 | #3745 |
| adult air | #3751 |
| suture techniques | #3751 |
| signs symptoms | #3758 |
| pm25 | #3770 |
| situ nickend | #3772 |
| management disease | #3773 |
| helper type | #3773 |
| anterior segment | #3782 |
| hydrochloride | #3792 |
| lenses | #3815 |
| docosahexaenoic acid dha | #3823 |
| perennial | #3824 |
| patients examined | #3835 |
| amniotic | #3843 |
| studies severity | #3851 |
| intercellular adhesion molecule | #3865 |
| interleukin13 | #3866 |
| strabismus | #3900 |
| diseases study | #3906 |
| complications observed | #3914 |
| mann | #3916 |
| interleukin2 interleukin4 | #3949 |
| specific ige | #3951 |
| subjects included | #3968 |
| cell expression | #3989 |
| chemokines | #3992 |
| microscopy | #3992 |
| discontinued treatment | #3993 |
| break | #3994 |
| lower compared | #3996 |
| studies roc | #3998 |
| ulcer | #4009 |
| cells hla | #4035 |
| female flow | #4036 |
| echinocandins | #4040 |
| acrylic resins | #4047 |
| immunosuppressive | #4068 |
| readings | #4071 |
| steroid | #4091 |
| subjects methods | #4093 |
| steroid treatment | #4095 |
| acinar | #4097 |
| discontinue | #4100 |
| inflammatory disorders | #4103 |
| tended higher | #4106 |
| ige | #4116 |
| bronchial asthma | #4135 |
| th2 | #4137 |
| severe effects | #4168 |
| female glaucoma | #4179 |
| aged sensitivity | #4189 |
| α induced | #4193 |
| papillary | #4193 |
| male surveys | #4211 |
| measured enzyme | #4218 |
| percentages | #4223 |
| visual acuity | #4239 |
| gamma interleukin1 | #4281 |
| heidelberg | #4286 |
| adult antibody | #4327 |
| purpose report | #4328 |
| clinically diagnosed | #4349 |
| visual function | #4360 |
| edema | #4368 |
| effective improving | #4382 |
| 11 patients | #4410 |
| reaction rna | #4417 |
| infiltrates | #4459 |
| interleukin | #4482 |
| healed | #4489 |
| conclusions clinical | #4503 |
| studies environmental | #4513 |
| scores | #4515 |
| gamma interleukin4 | #4530 |
| 14 28 | #4549 |
| baseline 2 | #4575 |
| excimer | #4592 |
| viral respiratory | #4601 |
| surface reconstruction | #4608 |
| blinding | #4654 |
| years recruited | #4660 |
| lid | #4671 |
| cytometric | #4683 |
| studies prosthesis | #4704 |
| patients bilateral | #4711 |
| chemotactic | #4713 |
| treatment conclusions | #4714 |
| 4 9 | #4720 |
| tomography optical | #4729 |
| immunoenzyme | #4748 |
| dermatitis contact | #4754 |
| 36 years | #4755 |
| 80 child | #4790 |
| glaucoma patients | #4793 |
| purpose assess | #4807 |
| healthy control subjects | #4826 |
| patients administration | #4833 |
| 111 patients | #4837 |
| immunoenzyme techniques | #4857 |
| protein array | #4864 |
| allergy | #4868 |
| fluoresceins fluorescent | #4892 |
| adult biological | #4902 |
| chronic gvhd | #4913 |
| foreign body | #4922 |
| defensins | #4929 |
| infrared rays | #4946 |
| scale 0 | #4948 |
| logarithm | #4974 |
| lower density | #5019 |
| months treatment | #5023 |
| nitrogen dioxide | #5023 |
| optical coherence | #5029 |
| groups compared | #5036 |
| opacities | #5052 |
| enterotoxins | #5054 |
| safety treatment | #5056 |
| unpaired | #5095 |
| amnion | #5097 |
| induced male | #5101 |
| strip | #5103 |
| lipopeptides | #5119 |
| glaucoma | #5131 |
| purposewe | #5143 |
| receptors chemokine | #5174 |
| patients 100 | #5189 |
| steroids | #5194 |
| epithelium | #5224 |
| thirtysix patients | #5224 |
| observed 2 | #5246 |
| determine efficacy | #5268 |
| lysine male | #5269 |
| child combined | #5301 |
| analysis reverse | #5302 |
| 2 weeks | #5303 |
| enzyme linked | #5314 |
| time measurements | #5318 |
| 74 years | #5320 |
| humans hyperthermia | #5365 |
| imidazoles male | #5366 |
| 20 25 | #5367 |
| allergen | #5403 |
| metaplasia | #5404 |
| agents chronic | #5423 |
| factors visual | #5431 |
| procedures postoperative | #5475 |
| differential disease | #5487 |
| igg anti | #5508 |
| keratitis | #5509 |
| alum | #5527 |
| mucin1 | #5530 |
| treatment follow | #5537 |
| barr virus | #5547 |
| humans lasers | #5560 |
| epithelial barrier | #5584 |
| counted | #5606 |
| visual analog scale | #5621 |
| spearman correlation | #5634 |
| aims evaluate | #5656 |
| giant | #5659 |
| publication administration | #5662 |
| il13 | #5676 |
| sutures | #5684 |
| eye proteins | #5692 |
| opacity | #5697 |
| histamine antagonists | #5721 |
| tonometry | #5735 |
| techniques cells | #5746 |
| th2 cells | #5747 |
| grades | #5747 |
| adult cell | #5754 |
| 889 | #5801 |
| male time | #5839 |
| tgfbeta1 | #5853 |
| sickness impact | #5861 |
| icam1 | #5871 |
| agents candida | #5881 |
| score 3 | #5903 |
| biomarkers case | #5924 |
| expression alpha | #5963 |
| nsaid | #5969 |
| antibody anti | #5999 |
| microscopy study | #6002 |
| chemotactic factors | #6005 |
| ip10 | #6027 |
| adverse health effects | #6035 |
| rhinitis allergic | #6041 |
| humans hyaluronic | #6046 |
| higher compared | #6074 |
| exacerbate | #6114 |
| controlled clinical | #6123 |
| baseline 1 | #6145 |
| placebo treatment | #6146 |
| thickening | #6158 |
| male neutrophils | #6171 |
| patients refractory | #6181 |
| treatment adverse | #6199 |
| desiccation | #6204 |
| resultsthe | #6224 |
| genetic adolescent | #6226 |
| diagnostic techniques | #6234 |
| efficacy | #6247 |
| impact profile | #6258 |
| subjects randomized | #6267 |
| johnson | #6274 |
| steroidal | #6295 |
| cells lymphocytes | #6296 |
| patients control | #6337 |
| dosed | #6343 |
| allergies | #6348 |
| ocular hypertension | #6376 |
| 005 conclusion | #6428 |
| ulceration | #6435 |
| japan male | #6443 |
| asthmatic agents | #6445 |
| wearing | #6466 |
| 2 groups | #6475 |
| air pollution | #6514 |
| house dust | #6543 |
| rejection humans | #6543 |
| primary human | #6559 |
| diclofenac | #6566 |
| 3 groups | #6582 |
| anti asthmatic | #6611 |
| glucocorticoids humans | #6618 |
| linked immunosorbent | #6618 |
| 3 months | #6643 |
| conventional therapy | #6652 |
| immunosorbent assay | #6675 |
| humans japan | #6704 |
| months compared | #6704 |
| inflammatory | #6764 |
| chemokine | #6774 |
| graded | #6779 |
| breakup | #6780 |
| severe | #6799 |
| serum total | #6811 |
| 1 14 | #6842 |
| male microscopy | #6859 |
| treatment refractory | #6864 |
| bcva | #6877 |
| enzymelinked immunosorbent assay | #6904 |
| conventional treatment | #6981 |
| wear | #7013 |
| adhesion molecules | #7016 |
| years treated | #7049 |
| contrast sensitivity | #7060 |
| observed treatment | #7063 |
| humans hypothermia | #7079 |
| 6 patients | #7102 |
| epsteinbarr virus | #7188 |
| transplantation child | #7270 |
| patients 9 | #7284 |
| water loss | #7310 |
| infections herpesvirus | #7328 |
| viral female | #7329 |
| treatment period | #7342 |
| syndromes | #7375 |
| photography | #7394 |
| severity | #7473 |
| relief | #7481 |
| seasonal | #7483 |
| alpha regulation | #7520 |
| confocal microscopy | #7575 |
| epithelial | #7618 |
| humans immunoglobulin | #7674 |
| inflammatory agents | #7677 |
| autumn | #7680 |
| treatment decreased | #7714 |
| calcineurin inhibitors | #7727 |
| 16 patients | #7794 |
| hyperthermia induced | #7892 |
| cyclosporine | #7933 |
| epstein barr | #8024 |
| steroidal anti | #8072 |
| tnfalpha | #8140 |
| methods fifty | #8160 |
| fk506 | #8206 |
| aged minimally | #8301 |
| barr | #8314 |
| production human | #8367 |
| assess safety | #8419 |
| evaluate effectiveness | #8448 |
| purpose | #8455 |
| patients normal | #8497 |
| regulation vascular | #8551 |
| statistically differences | #8556 |
| hypothermia induced | #8648 |
| graft rejection | #8670 |
| hladr | #8682 |
| corticosteroid | #8683 |
| epithelial cells | #8827 |
| score 1 | #8860 |
| design prospective | #8861 |
| year male | #8873 |
| ceramides | #8893 |
| capsular | #8909 |
| ovalbumin | #8972 |
| silicone | #8991 |
| anti inflammatory | #9041 |
| surgical flaps | #9087 |
| 3 6 | #9098 |
| complaints | #9098 |
| illness adolescent | #9141 |
| immunosorbent | #9162 |
| humidity | #9176 |
| cutoff values | #9181 |
| patients 16 | #9191 |
| 4 12 | #9193 |
| treatment adolescent | #9195 |
| 0 3 | #9331 |
| wilcoxon | #9408 |
| 375 | #9414 |
| virus ebv | #9435 |
| 8 patients | #9463 |
| humans intraoperative | #9556 |
| hypersensitivity | #9569 |
| reaction tumor | #9638 |
| adult anti | #9709 |
| particulate matter | #9803 |
| superficial | #9826 |
| refraction | #9835 |
| methods prospective | #9836 |
| anesthetics local | #9840 |
| limbic | #9855 |
| fluorescent dyes | #9935 |
| term treatment | #10001 |
| objectively | #10055 |
| postoperatively | #10097 |
| technique indirect | #10132 |
| symptoms patients | #10143 |
| 1year followup | #10154 |
| 10 minutes | #10161 |
| foreign | #10171 |
| factor vegf | #10178 |
| biomarkers child | #10229 |
| antigens humans | #10284 |
| compared treatment | #10317 |
| rhinitis | #10337 |
| glands | #10364 |
| cytokines | #10378 |
| week 4 | #10414 |
| common complication | #10417 |
| questionnaire | #10420 |
| shortterm | #10427 |
| mast cells | #10496 |
| lens | #10588 |
| subjects age | #10599 |
| longterm treatment | #10644 |
| chamber | #10647 |
| male prospective | #10703 |
| volunteers | #10707 |
| substance | #10715 |
| compared controls | #10729 |
| nsaids | #10777 |
| cells th2 | #10778 |
| filtering | #10900 |
| metabolism male | #10953 |
| il5 | #11022 |
| examinations | #11187 |
| patient demographics | #11192 |
| 20 40 | #11212 |
| body temperature | #11219 |
| complications retrospective | #11251 |
| eczema | #11287 |
| patients 4 | #11337 |
| purposeto | #11381 |
| nonsteroidal | #11393 |
| corrected | #11394 |
| mast | #11549 |
| interleukin8 | #11599 |
| eosinophilic | #11723 |
| adjunctive | #11730 |
| receptors immunologic | #11956 |
| longterm outcomes | #12069 |
| evaluate | #12086 |
| grading | #12107 |
| coherence | #12125 |
| prospective | #12163 |
| 0001 conclusions | #12216 |
| csa | #12259 |
| asthmatic | #12282 |
| sickness | #12312 |
| tnf α | #12395 |
| thirty | #12576 |
| volunteers humans | #12586 |
| evaluate effects | #12612 |
| elisa | #12717 |
| mucous | #12766 |
| tnfα | #12781 |
| agents anti | #12822 |
| evaluate safety | #12879 |
| host disease | #12922 |
| seconds | #13199 |
| minutes | #13216 |
| complications diabetes | #13262 |
| epithelia | #13267 |
| 4 weeks | #13267 |
| 005 | #13326 |
| tests performed | #13356 |
| 1 3 | #13413 |
| 2 cases | #13447 |
| underwent | #13549 |
| western blot analysis | #13578 |
| prosthesis design | #13600 |
| cultured coculture | #13613 |
| particulate | #13632 |
| clinical examination | #13829 |
| life surveys | #13937 |
| mast cell | #13997 |
| study clinical | #14017 |
| dogs female | #14046 |
| graft host | #14084 |
| 60 patients | #14391 |
| myopia | #14577 |
| diseases diabetes | #14729 |
| vascular cell | #14846 |
| spearman | #14877 |
| implantation | #14889 |
| infections staphylococcus | #15065 |
| hyaluronic | #15111 |
| allograft | #15158 |
| patients follow | #15344 |
| visual | #15382 |
| refractory | #15389 |
| burning | #15485 |
| discontinued | #15495 |
| 1 2 | #15658 |
| longterm | #15717 |
| 006 | #15839 |
| graft | #15913 |
| tnf alpha | #16084 |
| radiation injuries | #16251 |
| patients divided | #16456 |
| 32 patients | #16659 |
| 15 patients | #16684 |
| adhesion molecule1 | #16940 |
| herpesvirus 4 | #16966 |
| evaluate efficacy | #17035 |
| 4 human | #17084 |
| patients assigned | #17274 |
| noninvasive | #17324 |
| molecule1 | #17435 |
| antibiotics antineoplastic | #17587 |
| histopathologic | #17743 |
| acid male | #17891 |
| method female | #17912 |
| anterior | #17986 |
| symptoms | #18008 |
| inflammation | #18029 |
| healthy | #18209 |
| morphologic | #18280 |
| stained | #18391 |
| alkylating | #18391 |
| vegf | #18469 |
| 0001 | #18534 |
| cold temperature | #18622 |
| 00001 | #18681 |
| 9 patients | #18689 |
| neovascularization | #19381 |
| female fluorescent | #19461 |
| stromal | #19499 |
| aged postoperative | #19510 |
| lipids male | #19666 |
| endothelial growth | #19723 |
| nerve fibers | #19872 |
| follow period | #19917 |
| artificial | #20012 |
| female graft | #20067 |
| 24 patients | #20143 |
| count cell | #20148 |
| epithelial cell | #20437 |
| complications prospective | #20558 |
| patients evaluated | #20800 |
| 22 patients | #21524 |
| 003 | #21648 |
| daily | #22391 |
| gland | #22647 |
| followup period | #22674 |
| male middle aged | #22802 |
| ifngamma | #23824 |
| outcome measures | #24510 |
| enrolled | #24838 |
| transplantation homologous | #25557 |
| patients adolescent | #25760 |
| adult body | #25783 |
| adult analysis | #26261 |
| conclusions patients | #26516 |
| adult biomarkers | #29382 |
| statistically | #29861 |
| age matched | #29948 |
| humans inflammation | #30660 |
| cells female | #31500 |
Sacar un reporte | |
Prominent publications by Hiroshi Fujishima
KOL-Index: 19369
PURPOSE: To describe MUC5AC alterations and the ocular surface disorder in atopic patients with or without corneal ulcers.
METHODS: Atopic patients' eyes were divided into two groups according to the presence and absence of corneal ulceration. The subjects underwent corneal sensitivity measurements, Schirmer test, tear film break-up time (BUT), fluorescein and Rose Bengal staining of the ocular surface and conjunctival impression cytology and brush cytology. Impression cytology samples ...
| Conocido por Ocular Surface | Eyes Corneal Ulcers | Atopic Patients | Brush Cytology | Akc Vkc |
Application of Visante Optical Coherence Tomography Tear Meniscus Height Measurement in the Diagnosis of Dry Eye Disease
[ PUBLICATION ]
PURPOSE: To investigate the applicability of tear meniscus height (TMH) measurement using Visante optical coherence tomography (OCT) in the diagnosis of dry eye disease.
DESIGN: Prospective, controlled, single-center study.
PARTICIPANTS: Twenty-four right eyes of 24 patients (6 males, 18 females; mean age, 63.14±13.4 years) with definite dry eye according to the Japanese dry eye diagnostic criteria and 27 right eyes of 27 control subjects (12 males, 15 females; mean age, 56.04±14.22 ...
| Conocido por Dry Eye Disease | Coherence Tomography | Tear Meniscus Height | Sensitivity Specificity | Strip Meniscometry |
Evaluation of lipid oxidative stress status and inflammation in atopic ocular surface disease.
[ PUBLICATION ]
BACKGROUND: Although the oxidative stress status in atopic skin disease has been reported to be elevated, there are still no studies related to the status of oxidative stress in atopic ocular surface disease. The purpose of this study was to evaluate the ocular surface lipid oxidative stress status and inflammation in atopic keratoconjunctivitis (AKC) patients and normal subjects.
METHODS: Twenty eight eyes of 14 patients (9 males, 5 females) with AKC and 18 eyes of 9 age and sex matched ...
| Conocido por Oxidative Stress | Akc Patients | Surface Disease | Inflammatory Cells | 5 Females |
KOL-Index: 11411
PURPOSE: To evaluate the effectiveness and safety of a novel cyclosporine 0.1% aqueous ophthalmic solution in a large population with vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC).
METHODS: A prospective observational postmarketing study was initiated in Japan. A total of 594 patients with VKC or AKC were started on this drug within 1 year after market launch (January 2006) and completed a 6-month follow-up. These patients were observed clinically, and ...
| Conocido por Vkc Akc | Allergic Conjunctivitis | Topical Steroids | 1 Month | Objective Signs |
Alterations of the ocular surface epithelial MUC16 and goblet cell MUC5AC in patients with atopic keratoconjunctivitis
[ PUBLICATION ]
BACKGROUND: An increased understanding of the ocular surface at cellular level in the conjunctiva and the cornea may help explain the pathogenesis and the subsequent clinical appearance of atopic ocular allergies, which may be potentially blinding.
PURPOSE: To investigate the MUC16 and MUC5AC alterations, tear function and the ocular surface disorder in patients with atopic keratoconjunctivitis (AKC).
METHODS: Thirty-six eyes of 18 AKC patients as well as 28 eyes of 14 age- and ...
| Conocido por Atopic Keratoconjunctivitis | Ocular Surface | Patients Akc | Muc5ac Muc16 | Goblet Cell |
KOL-Index: 10572
BACKGROUND: The pathogenesis of the ocular surface disease in atopic keratoconjunctivitis (AKC) and vernal keratoconjunctivitis (VKC) has not been fully understood. We tried to clarify the differences in the ocular surface status in patients with AKC, VKC, and healthy control subjects.
METHODS: Twenty-four eyes of 12 AKC patients, 12 eyes of six VKC patients, and 20 eyes of 10 normal control subjects were studied. The subjects underwent corneal sensitivity measurements, Schirmer test, ...
| Conocido por Ocular Surface | Atopic Keratoconjunctivitis | Patients Akc | Eyes Vkc | Brush Cytology |
Alterations of the ocular surface epithelial mucins 1, 2, 4 and the tear functions in patients with atopic keratoconjunctivitis
[ PUBLICATION ]
BACKGROUND: An increased understanding of the ocular surface alterations at the cellular level in the conjunctiva and the cornea, may help explain the pathogenesis and the subsequent clinical appearance of atopic ocular allergies, which may be potentially blinding.
PURPOSE: To investigate MUC 1, 2 and 4 alterations, tear function and the ocular surface disorder in patients with atopic keratoconjunctivitis.
METHODS: Twenty-eight eyes of 14 atopic keratoconjunctivitis patients as well as ...
| Conocido por Atopic Keratoconjunctivitis | Ocular Surface | Brush Cytology | Corneal Sensitivity | Epithelial Mucins |
KOL-Index: 10372
PURPOSE: To prospectively assess the clinical outcome after implantation of the 1CU accommodating intraocular lens (IOL) and a foldable acrylic IOL (AcrySof, Alcon).
SETTING: Department of Ophthalmology, Tokyo Dental College, Ichikawa Hospital, Ichikawa, and Minami Aoyama Eye Clinics, Tokyo, Yokohama, Japan.
METHODS: Twenty-two eyes of 16 patients with cataract had phacoemulsification implantation of 1CU accommodating IOL. Twenty eyes of 10 age-matched and sex-matched patients with ...
| Conocido por Intraocular Lens | Visual Acuity | 1cu Iol | Cataract Surgery | Amplitude Accommodation |
KOL-Index: 10324
PURPOSE: Eosinophils are known to have important roles in the pathogenesis of allergic conjunctivitis. Prostaglandin (PG) D2, which has been implicated as a factor in allergic diseases, is known to have chemotactic activity for eosinophils. Its receptor, chemoattractant receptor homologous molecule expressed on TH2 (CRTH2), serves as a receptor for PGD2 and has been reported to mediate PGD2-dependent migration of eosinophils. In the present study, both eosinophil toxic activity for ...
| Conocido por Receptor Crth2 | Chemotaxis Eosinophils | Allergic Conjunctivitis | Pgd2dependent Migration | Homologous Molecule |
A Randomized, Placebo-Controlled Clinical Trial of Tacrolimus Ophthalmic Suspension 0.1% in Severe Allergic Conjunctivitis
[ PUBLICATION ]
AIMS: To examine the efficacy of tacrolimus ophthalmic suspension 0.1% in treating severe allergic conjunctivitis.
METHODS: This was a multicenter, randomized, double-masked, placebo-controlled clinical trial. Fifty-six patients with severe allergic conjunctivitis in whom topical antiallergic agents and corticosteroids had been ineffective were randomized to tacrolimus or placebo treatment. Patients were treated either with tacrolimus or placebo twice-daily for 4 weeks. Severity of ...
| Conocido por Severe Allergic Conjunctivitis | Tacrolimus Ophthalmic | Objective Signs | Corneal Involvement | Clinical Trial |
TGF-beta1, IL-1beta, and Th2 cytokines stimulate vascular endothelial growth factor production from conjunctival fibroblasts
[ PUBLICATION ]
Giant papillary formation containing newly formed vessels is a major characteristic of severe allergic conjunctivitis, such as atopic keratoconjunctivitis (AKC) or vernal keratoconjunctivitis (VKC). We examined production of vascular endothelial growth factor (VEGF) from cultured conjunctival fibroblasts from normal volunteers under stimulation with type 1-, type 2-helper T cell derived and proinflammatory cytokines to investigate the mechanism of giant papillae formation in AKC/VKC. ...
| Conocido por Conjunctival Fibroblasts | Vascular Endothelial | Growth Factor | Vegf Concentration | Akc Vkc |
KOL-Index: 9650
PURPOSE: To prospectively assess the clinical and visual outcomes of phacoemulsification and implantation of a rollable intraocular lens (IOL) with a thin optic and compare the results with those of implantation of a foldable acrylic IOL.
SETTING: Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Chiba, Japan.
METHODS: Sixteen consecutive eyes of 8 patients (4 women, 4 men) with corticonuclear cataract had small-incision clear corneal ...
| Conocido por Intraocular Lens | Thinoptx Iol | Phacoemulsification Implantation | Visual Acuity | 6 Months |
Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease
[ PUBLICATION ]
We investigated the effect of 0.05% topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group (14 eyes of 7 patients) and control group (12 eyes of 6 patients) respectively. Two patients dropped out because of intolerable irritation while using topical Cys eye drops. ...
| Conocido por Ocular Surface | Topical Cyclosporine | Eye Patients | Chronic Graft | Host Disease |
Measurement of IL‐4 in tears of patients with seasonal allergic conjunctivitis and vernal keratoconjunctivitis
[ PUBLICATION ]
To elucidate the mechanism of ocular surface allergic disease, we focused on IL-4, which is one of the key factors in regulating IgE production, and thus determined the concentration of IL-4 in tears. IL-4 concentration was determined in the tears of 15 patients with seasonal allergic conjunctivitis, 15 vernal keratoconjunctivitis (VKC), 10 giant papillary conjunctivitis (GPC), 10 patients with non-allergic conjunctivitis and post-cataract surgical conjunctivitis as intermediate ...
| Conocido por Allergic Conjunctivitis | Tears Patients | Vkc Gpc | Normal Controls | Linked Immunosorbent |
Gente clave para Allergic Conjunctivitis
Los KOLs mas influyentes del mundo
Seleccione una frase de búsqueda allergic conjunctivitis , allergic conjunctivitis asthma , allergic conjunctivitis mice , allergic conjunctivitis children , allergic conjunctivitis patients
Hiroshi Fujishima:Impacto experto
Conceptos para los cualesHiroshi Fujishimatiene influencia directa:Allergic conjunctivitis, Dry eye, Atopic keratoconjunctivitis, Conjunctival fibroblasts, Allergic conjunctival disease, Brush cytology, Ocular surface, Vernal keratoconjunctivitis.
Hiroshi Fujishima:Impacto de Kol
Conceptos relacionados con el trabajo de otros autores para los cualesfor which Hiroshi Fujishima tiene influencia:Dry eye, Ocular surface, Allergic conjunctivitis, Tear film, Amniotic membrane, Cataract surgery, Contact lens.
Tools
¿Es este tu perfil? Reclama tu perfil Copiar URL Incrustar el enlace a su perfil |